

Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials

Lihu Gu^{1†}, Rongrong Fu^{2†}, Jiaze Hong³, Haixiang Ni⁴, Kepin Yu² and Haiying Lou^{5*}

¹ Department of General Surgery, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo, China, ² The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China, ³ The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China, ⁴ The Department of Endocrinology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China, ⁵ Department of Endocrinology, Zhuji People's Hospital, Shaoxing, China

OPEN ACCESS

Edited by:

Leigh Gibson, University of Roehampton London, United Kingdom

Reviewed by:

Mojtaba Kaviani, Acadia University, Canada Evelyn Parr, Australian Catholic University, Australia

> *Correspondence: Haiying Lou zjzyydx255@163.com

[†]These authors have contributed equally to this work and share first authorship

Specialty section:

This article was submitted to Eating Behavior, a section of the journal Frontiers in Nutrition

Received: 08 February 2022 Accepted: 28 March 2022 Published: 02 May 2022

Citation:

Gu L, Fu R, Hong J, Ni H, Yu K and Lou H (2022) Effects of Intermittent Fasting in Human Compared to a Non-intervention Diet and Caloric Restriction: A Meta-Analysis of Randomized Controlled Trials. Front. Nutr. 9:871682. doi: 10.3389/fnut.2022.871682 **Background:** The popularity of applying intermittent fasting (IF) has increased as more and more people are trying to avoid or alleviate obesity and metabolic disease. This study aimed to systematically explore the effects of various IF in humans.

Methods: The randomized controlled trials (RCTs) related to IF vs. non-intervention diet or caloric restriction (CR) were retrieved in PubMed, Web of Science, Cochrane Library database, and Embase. Extraction outcomes included, but were not limited to, weight, body mass index (BMI), waist circumference (WC), fasting glucose, and triglyceride (TG).

Results: This study includes 43 RCTs with 2,483 participants. The intervention time was at least 1 month, and the median intervention time was 3 months. Contrasting results between IF and non-intervention diet showed that participants had lower weight (weighted mean difference (WMD) = 1.10, 95% CI: 0.09–2.12, p = 0.03) and BMI after IF (WMD = 0.38, 95% CI: 0.08–0.68, p = 0.01). The WC of participants after IF decreased significantly compared with the non-intervention diet (WMD = 1.02, 95% CI: 0.06–1.99, p = 0.04). IF regulated fat mass (FM) more effectively than nonintervention diet (WMD = 0.74, 95% CI: 0.17-1.31, p = 0.01). The fat-free mass of people after IF was higher (WMD = -0.73, 95% CI: (-1.45)–(-0.02), p = 0.05). There was no difference in fasting blood glucose concentrations between participants in the after IF and non-intervention diet groups. The results of insulin concentrations and HOMA-IR, though, indicated that IF was significantly more beneficial than nonintervention diet (standard mean difference (SMD) = -0.21, 95% CI: 0.02–0.40, p = 0.03, and WMD = 0.35, 95% CI: 0.04–0.65, p = 0.03, respectively). Cholesterol and TG concentrations in participants after IF were also lower than that after a nonintervention diet (SMD = 0.22, 95% CI: 0.09-0.35, p = 0.001 and SMD = 0.13, 95% CI: 0.00-0.26, p = 0.05, respectively). IF outcomes did not differ from CR except for reduced WC.

1

Conclusion: Intermittent fasting was more beneficial in reducing body weight, WC, and FM without affecting lean mass compared to the non-intervention diet. IF also effectively improved insulin resistance and blood lipid conditions compared with non-intervention diets. However, IF showed less benefit over CR.

Keywords: intermittent fasting, non-intervention diet, caloric restriction, effect, meta-analysis

INTRODUCTION

Recently, the number of patients with metabolic diseases and obesity around the world has increased significantly (1). Numerous treatments for these kinds of diseases mostly focus on diet and exercise (2, 3). Intermittent fasting (IF) has become a popular lifestyle in recent years, though it has existed in religious and cultural contexts for a long time (4, 5). IF is a term that covers several specific patterns (6, 7). Alternateday fasting (ADF), intermittent energy restriction (IER), timerestricted feeding (TRF), and Ramadan fasting are currently recognized as the several subtypes of IF (7, 8). ADF consists of alternating fasting days and eating days, while TRF refers to the daily free energy intake within a specific time window of 4-12 h (8). Ramadan fasting refers to one meal only before dawn or after sunset (8, 9). There is also a modified fasting regime that differs from the previous ones in terms of not taking in any energy during the fasting period and eating food with extremely low calories 2 or 3 days per week (8).

Intermittent fasting is a specific strategy to reduce energy intake *via* fasting and, therefore, reduce weekly energy intake. It has been an attemption in patients with overweight or obese to achieve weight loss (6). Caloric restriction (CR), which is considered the standard dietary strategy to lose or maintain weight, has been discovered to be difficult in maintaining among many individuals, and the likelihood of late weight rebound when it comes to long-term use. Thus, a combination of intermittent CR and temporal control was proposed to replace a simple long-term regimen of CR (10, 11).

A meta-analysis reported that ADF can result in better compliance and more reduced fat mass (FM) than CR in patients (11). Furthermore, a recent investigation into TRF has illustrated its effectiveness in weight loss (12). Although some studies have revealed the effects of certain fasting patterns, comprehensive systematic reviews of IF are limited and in need. Therefore, herein, we attempted to explore the effects of IF on humans systematically and quantitatively.

METHODS

Literature Search Strategy

Two researchers independently screened the literature related to IF from PubMed, Web of Science, Cochrane Library database, and Embase. All selected literature was published before June 2021. The keywords used in the search were "randomized controlled trial" OR "controlled clinical trial" OR "randomized" OR "placebo" OR "clinical trials as topic OR randomly" OR "trial" AND "fasting" OR "intermittent* fast*" OR "fast* diet*" OR "alternat* fast*" OR "modified fast*" OR "food abstinence" OR "food fast*" OR "diet* restricti*" OR "food restricti*" OR "time restricted feed*" OR "time restricted fast*" OR "timerestricted eating" OR "one whole day fast*" OR "food tim*" OR "Ramadan" OR "Ramadhan" OR "Ramadan fasting" OR "Islamic fasting" OR "Ramadan intermittent fasting" OR "Ramadan diurnal fasting" OR "Ramadan model of intermittent fasting" OR "intermittent prolonged fasting during Ramadan" OR "Ramadan fast" OR "recurrent circadian fasting." The references in the relevant literature were screened additionally to expand the library of relevant literature. The study guideline was Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) (13).

Inclusion Criteria and Exclusion Criteria

Literature meeting all the following criteria would be included: (1) The intervention group included but was not limited to ADF, TRF, IER, and Ramadan fasting, while the control group was the non-intervention diet or CR. (2) The study provided physical and biochemical parameters of the subjects in both the intervention group and the control group after intervention. (3) The follow-up time was at least 1 month. (4) Data were available.

The study would be excluded once it met any of the following criteria: (1) The study was not a randomized controlled trial (RCT). (2) The research individual was not human. (3) The full text of the article was not in English. (4) The literature was duplicated.

Quality Assessment and Data Extraction

The quality of screened RCTs was evaluated using the Cochrane Collaboration's tool (14). Two investigators independently assessed the risk of study bias. Controversies were decided by a third researcher. Study characteristics (author, year, country, trial registration, patient inclusion criteria, intervention, control, and follow-up) and physical parameters [weight, body mass index (BMI), waist circumference (WC)], biochemical parameters [fasting insulin, fasting glucose, total cholesterol (TC), and triglyceride (TG)] were extracted from the included studies.

Abbreviations: IF, intermittent fasting; ADF, alternate-day fasting; IER, intermittent energy restriction; TRF, time-restricted feeding; CR, caloric restriction; FM, fat mass; RCT, randomized controlled trial; BMI, body mass index; WC, waist circumference; TC, total cholesterol; TG, triglyceride; WMD, weighted mean difference; SMD, the standard mean difference; CI, confidence intervals; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoprotein.



Intermittent fasting patterns were diverse, and the current major dietary patterns were ADF, TRF, IER, and Ramadan fasting (7, 8). This study was roughly divided into daily TRF, weekly TRF, ADF, and Ramadan fasting based on the time and frequency of fasting with IF. Among these, daily TRF referred to a feeding window of 4–12 h per day and fasting for the remaining of the day. Weekly TRF referred to fasting for 2–3 days per week consisting of a 5:2 diet and a 3:4 diet. Control group dietary patterns were diverse, including groups following uncontrolled habitual "non-intervention diets," "calorie restriction," "continuous energy restriction," and "daily energy

restriction" groups: the last three are referred to in this study as CR.

Statistical Analysis

Review Manager 5.3 was used for statistical analysis. The weighted mean difference (WMD) and the standard mean difference (SMD) were calculated for continuous data. The 95% confidence intervals (CIs) for all statistical results were provided. I^2 was used to represent the heterogeneity of the results. When $I^2 > 50$, the random-effect model was used, otherwise, the fixed-effect model was used. p < 0.05 was considered to be statistically significant. Sensitivity analysis

was performed by removing the included studies one by one. Meanwhile, funnel plots were used to examine publication bias (15).

RESULTS

Study Characteristics

After retrieval and elimination of duplicates, a total of 24,887 articles were screened. Then, 24,729 of them were excluded based on their irrelevant title and abstract. After thoroughly viewing the full text of the remaining 158 articles, 115 of them were excluded, of which 85 were excluded due to lack of relevant results, 4 exclusions were due to non-RCTs, 2 were excluded due to unavailable data. Finally, 43 RCTs (3, 6, 7, 9, 16–54) were included in our meta-analysis. The detailed retrieval process and elimination reasons are recorded in the flowchart (**Figure 1**).

Characteristics of included RCTs in the meta-analysis were recorded in **Table 1**. A total of 2,483 participants were included in the analysis, with 1,277 in the intervention group and 1,206 in the control group. Interventions included weekly TRF, daily TRF, ADF, and Ramadan fasting. Eating patterns in the control group included non-intervention diet and CR. Non-intervention diet referred to the usual diet without any intervention in the subjects. CR included continuous energy restriction, a Mediterranean diet, and Dietary Approaches to Stop Hypertension (DASH). The included studies were followed for at least 1 month, with a median follow-up of 3 months. Participants in this study came from Brazil, China, Germany, Iran, Italy, Korea, Malaysia, New Zealand, Norway, Spain, Tunisia, Turkey, the UK, and the USA.

Risk of Bias

Quality assessment of studies included is shown in **supplementary Table 1**. The Cochrane Collaboration's tool was used to assess the risk of bias in studies. Most studies were at low risk in sequence generation and allocation concealment. Only one study showed unclear risk in sequence generation due to incomplete information. As for blinding of the risk of bias, 10 trials were evaluated as high, 15 were unclear, and the rest 18 studies were low. Notably, 43 studies were at low risk for incomplete outcome data and selective outcome reporting. As for free of other bias, one was at high risk, 15 were at unclear risk, and the remaining 27 were at low risk.

IF vs. Non-intervention Diet

Nineteen studies reported the weight of participants after IF and for those who maintained the non-intervention diet. The results illustrated that IF induced greater weight loss (WMD = 1.10, 95% CI: 0.09–2.12, p = 0.03) (**supplementary Table 2**). For BMI, the collective analysis of BMI as a result of following the IF diets resulted in greater reductions in BMI compared to the BMI following habitual diets (WMD = 0.38, 95% CI: 0.08–0.68, p = 0.01) (**Figure 2A**). In addition, participants who received IF had smaller WC after the experiment compared to those who had undergone the non-intervention diet (WMD = 1.02, 95% CI: 0.06-1.99, p = 0.04) (**Figure 2B**).

In terms of body composition, the participants in the IF group had less FM than those in the non-intervention diet group after interventions (WMD = 0.74, 95% CI: 0.17-1.31, p = 0.01) (Figure 3A). The fat-free mass (FFM) of participants who underwent IF was greater than that of those in the nonintervention diet group, demonstrating that IF had less effect on the FFM (WMD = -0.73, 95% CI: (-1.45)-(-0.02), p =0.05) (Figure 3B). However, for FM percentage (FM%) after the intervention, there was no significant difference between IF and non-intervention diet groups (WMD = 0.38, 95% CI: (-0.14)-0.89, p = 0.16 (supplementary Table 2). Ten studies provided data on systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the participants after the intervention. The results revealed that neither SBP nor DBP was affected via IF or non-intervention diet (WMD = 1.32, p = 0.33, and WMD = 0.96, p = 0.39, respectively) (supplementary Table 2).

Sixteen studies examined the effects of IF and the nonintervention diet on the fasting glucose concentrations of participants, where no difference was observed (SMD = -0.00, 95% CI: (-0.14)-0.13, p = 0.94) (**Figure 4A**). Thirteen studies investigated the effects of IF and non-intervention diet on insulin concentrations in participants. The correlated systematic analysis showed that the insulin levels after IF were significantly lower than those after the non-intervention diet (SMD = -0.21, 95% CI: 0.02-0.40, p = 0.03) (**Figure 4B**). In addition, the result of homeostasis model assessment insulin resistance (HOMA-IR) from 8 studies showed that IF could reduce insulin resistance more effectively compared to the non-intervention diet (WMD = 0.35, 95% CI: 0.04-0.65, p = 0.03; $I^2 = 0\%$) (**Figure 4C**).

Eighteen studies provided the fasting TG concentrations of participants following IF and the non-intervention diet, and IF was proved to be significantly more effective in reducing TG in participants (SMD = 0.22, 95% CI: 0.09–0.35, p = 0.001) (**Figure 5A**). Eighteen studies reported the TC concentrations in IF group and non-intervention diet group, and the results indicated that participants had significantly lower TC in the former case (SMD = 0.13, 95% CI: 0.00–0.26, p = 0.05; $I^2 = 26\%$) (**Figure 5B**). In addition, 17 and 16 studies reported statistical results for low-density lipoprotein (LDL) and high-density lipoprotein (HDL), respectively. The statistical difference of those parameters between groups of IF and non-intervention diet was discovered in neither aspect (SMD = 0.10, p = 0.42, and SMD = -0.03, p = 0.63, respectively) (**supplementary Table 2**).

IF vs. CR

The physical and biochemical parameters of IF vs. CR were analyzed in this study. The result of 10 studies showed that IF reduced participants' WC more than CR. The result was statistically significant with low heterogeneity (WMD = 2.29, 95% CI: 0.57–4.01, p = 0.009; $I^2 = 35\%$). Moreover, no difference was observed between IF and CR in terms of weight, glucose, and blood lipids between groups. Details of the results are shown in **Table 2**.

Subgroup Analysis

The main pattern of IF in this study was ADF and weekly TRF, so they were compared with CR separately. The physical

TABLE 1 | Characteristics of included RCTs in the meta-analysis.

References	Country Trial registration Patient in criteria		Patient inclusion criteria	Inter	vention	Control		Follow-up (month)
				Fasting patterns	N	Dietary patterns	Ν	
Antoni et al. (16)	UK	ISRCTN13687043	BMI>25 kg/m ² ; Age: 18–65 years	IER (2:5 diet)	24	CER	24	16
Beaulieu et al. (17)	UK	NCT03447600	BMI: 25–34.9 kg/m ² ; Age: 18–55 years	ADF	24	CER	22	10
Bhutani et al. (18)	USA	NA	BMI: 30–39.9 kg/m ² ; Age: 25–65 years	ADF	25	Non-intervention diet	16	3
Bowen et al. (19)	Australia	ACTRN12616000110482	BMI > 27 kg/m ² ; Age: 25–60 years	ADF+DER	82	DER	81	4
Cai et al. (20)	China	ChiCTR1900024411	BMI > 24 kg/m ² with NAFLD; Age: 18–65 years	ADF	95	Non-intervention diet	79	3
				TRF (16:8 diet)	97			
Carlson et al. (21)	USA	NA	BMI: 18–25 kg/m ² ; Age: 40–50 years	TRF (20:4 diet)) 15	Non-intervention diet	15	4
Catenacci et al. (22)	USA	NA	$BMI \ge 30 \text{ kg/m}^2; \text{ Age:} \\ 18-55 \text{ years}$	ADF	15	CR	14	8
Chow et al. (23)	USA	NCT03129581	$BMI \ge 25 \text{ kg/m}^2; \text{ Age:} \\ 18-65 \text{ years}$	TRF (16:8 diet)) 13	Non-intervention diet	9	3
Cienfuegos et al. (24)	USA	NCT03867773	BMI: 30–49.9 kg/m ² ; Age: 18–65 years	TRF (20:4 diet)) 19	Non-intervention diet	19	2
				TRF (18:6 diet) 20			_
Conley et al. (25)	Australia	ACTRN12614000396628	BMI \geq 30 kg/m ² ; Age: 55–75 years	IER (2:5 diet)	12	CR	12	6
Corley et al. (26)	New Zealand	ACTRN12614000402640	BMI: 30–45 kg/m ² with T2DM; Age > 18 years	nTRF (2:5 diet)	22	CR	19	4
Correia et al. (7)	USA	NA	Age: 18–30 years	TRF (16:8 diet)	9	Non-intervention diet	9	1
Coutinho et al. (27)	Norway	NCT02169778	BMI: 30–40 kg/m ² ; Age: 18–65 years	IER (3:4 diet)	18	CER	17	3
de Oliveira Maranhão Pureza et al. (44)	Brazil	NA	BMI: 30–45kg/m ²	TRF+CR (12:12 diet)	31	CR	27	12
Gabel et al. (28)	USA	NCT00960505	BMI: 25–39.9 kg/m ² ; Age: 18–65 years	ADF	34	CR	35	12
						Non-intervention diet	31	
Guo et al. (29)	China	NCT03608800	Age: 30–50 years with comorbidities	IF (2:5 diet)	23	Non-intervention diet	23	2
Harvie et al. (30)	UK	NA	BMI: 24–40kg/m ² ; Age: 30–45 years	IER (2:5 diet)	53	CER	54	6
Harvie et al. (31)	USA	ISRCTN52913838	BMI: 24–45 kg/m ² ; Age:20–65 years	IECR (2:5 diet)	37	DER	40	16
Headland et al. (3)	Australia	ACTRN12614001041640	$BMI \ge 27 \text{ kg/m}^2$; Age>18 years	IER (2:5 diet)	82	CER	81	13
Hirsh et al. (32)	USA	NCT03372109	BMI: 25–29.9 kg/m ² ; Age: 21–65 years	IF (2:5 diet)	10	Non-intervention diet	12	2
Kotarsky et al. (33)	USA	NCT03823872	BMI: 25–34.9 kg/m ² ; Age: 35–65 years	TRF (16:8 diet)) 13	Non-intervention diet	10	14
Kunduraci et al. (34)	Turkey	NCT04502329	$BMI \ge 27 \text{ kg/m}^2$ with comorbidities; Age: 18–65 years	IER (16:8 diet)	35	CER	35	3
Lowe et al. (35)	USA	NCT03393195	Age: 18–64	TRF (16:8 diet) 69	Non-intervention diet	72	3

(Continued)

TABLE 1 | Continued

References	Country	Trial registration	Patient inclusion criteria	Intervention		Control		Follow-up (month)
				Fasting patterns	N	Dietary patterns	Ν	
Martens et al. (35)	USA	NCT02970188	BMI < 40 kg/m ² ; Age: 55–79 years	TRF (16:8 diet)24	CR	24	2
Martínez-Rodríguez et al. (6)	Spain	NCT04404413	NA	IF	14	Non-intervention diet	14	4
McAllister et al. (37)	USA	NA	NA	TRF (16:8 diet)11	Non-intervention diet	12	1
Moro et al. (38)	Italy	NA	NA	TRF (16:8 diet) 17	Non-intervention diet	17	2
Moro et al. (39)	Italy	NCT04320784	Age < 23 years	TRF (16:8 diet)8	Non-intervention diet	8	1
Oh et al. (40)	Korea	NCT03652532	BMI > 23 kg/m ² ; Age: 18–64 years	ADF+CR	13	CR	10	2
Panizza et al. (41)	USA	NCT03639350	BMI: 25–40 kg/m ² ; Age: 35–55 years	IER+MED (2:5 diet)	5 30	DASH	30	6
Parvaresh et al. (42)	Iran	IRCT201509092395N8	BMI: 25–40 kg/m ² ; Age: 25–60 years	ADF	35	CR	35	2
Pureza et al. (43)	Brazil	RBR-387v6v	BMI: 30–45 kg/m ²	TRF+CR (12:12 diet)	31	CR	27	1
Razavi et al. (45)	Iran	NA	BMI: 25–40 kg/m ² witl MetS; Age: 25–60 years	h ADF	40	CR	40	4
Schübel et al. (46)	Germany	NCT02449148	BMI: 25–40 kg/m ² ; Age: 35–65 years	ICR (2:5 diet)	45	CR	49	12
						Non-intervention diet	52	
Stote et al. (47)	USA	NA	BMI: 18–25 kg/m ² ; Age: 40–50 years	TRF (20:4 diet) 15	Non-intervention diet	15	6
Teng et al. (49)	Malaysia	NA	BMI: 23–29.9 kg/m ² ; Age: 50–70 years	FCR (2:5 diet)	14	Non-intervention diet	14	3
Teng et al. (48)	Malaysia	NA	BMI: 23–29.9 kg/m ² ; Age: 50–70 years	FCR (2:5 diet)	28	Non-intervention diet	28	3
Tinsley et al. (50)	USA	NA	NA	TRF (20:4 diet + 4:3 diet)	14	Non-intervention diet	14	2
Tinsley et al. (51)	USA	NCT03404271	Age: 18–30 years	TRF (16:8 diet) 13	Non-intervention diet	14	2
Trabelsi et al. (9)	Tunisia	NA	NA	Ramadan	10	Non-intervention diet	9	1
Trabelsi et al. (52)	Tunisia	NA	NA	Ramadan	8	Non-intervention diet	8	1
Varady et al. (53)	USA	NA	BMI: 20–29.9 kg/m ² ; Age: 35–65 vears	ADF	16	Non-intervention diet	16	3
Zouhal et al. (54)	Tunisia	NA	BMI: 30–40 kg/m ²	Ramadan	14	Non-intervention diet	14	1

RCT, randomized controlled trial; IER, intermittent energy restriction; ADF, alternate-day fasting; DER, daily energy restriction; TRF, time-restricted feeding; NAFLD, nonalcoholic fatty liver disease; IF, intermittent fasting; CR, calorie restriction; MED, Mediterranean diet; MetS, metabolic syndrome; ICR, intermittent calorie restriction; FCR, Muslim sunnah fasting; UK, United Kingdom; USA, the United States; BMI, body mass index; NA, no available; CER, continuous energy restriction; ICER, intermittent energy and carbohydrate restriction; DASH, Dietary Approaches to Stop Hypertension; 2:5 diet, 2-day fasting per week; 16:8 diet, 16-h fasting per day; 20:8 diet, 20-h fasting per day; 18:6 diet, 18-h fasting per day; 3:4 diet, 3-day fasting per week; 12:12 diet, 12-h fasting per day; 4:3 diet, 4-day fasting per week; N, number of patients.

and biochemical parameters of participants in ADF and CR groups that were included in the investigation were weight, body composition, glucose, and blood lipids. According to the statistical results, there was no significant difference in all

parameters between the two groups. In other words, the effects of ADF and CR on participants were similar (**Table 3**). In addition, 8 studies compared post-intervention data of weekly TRF vs. CR. The statistical result of WC extracted from 6 studies showed that

	Non-I	nterven	tion		11-			Mean Difference	wean Differ	rence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 9	5% CI	
Bhutani 2013	35	4	16	34	4	16	1.1%	1.00 [-1.77, 3.77]		•	
Cai 2019	26.64	1.66	79	26.6	1.46	95	40.1%	0.04 [-0.43, 0.51]		-	
Cai 2019	26.64	1.66	79	26.15	1.58	90	36.7%	0.49 [-0.00, 0.98]			
Gabel 2019	35	3.87	15	32	3.32	11	1.1%	3.00 [0.23, 5.77]	-		•
Kotarsky 2021	29.3	2.85	10	28.8	2.65	11	1.6%	0.50 [-1.86, 2.86]			
Lowe 2020	31.1	3.43	24	30.9	3.27	22	2.4%	0.20 [-1.74, 2.14]			
Oh 2018	26.2	3	10	26.7	2.5	13	1.7%	-0.50 [-2.80, 1.80]			
Teng 2011	26.8	1.9	13	26.3	1.9	12	4.0%	0.50 [-0.99, 1.99]			
Teng 2013	26.7	2.2	28	25.9	1.9	28	7.6%	0.80 [-0.28, 1.88]		-	
Zouhal 2020	33.6	2.7	14	32.2	1.2	14	3.7%	1.40 [-0.15, 2.95]	+		-
Total (95% CI)			288			312	100.0%	0.38 [0.08, 0.68]	•		
10tal (3378 CI)											
Heterogeneity: Chi ² =	8.72, df =	= 9 (P =	0.46); l	² = 0%							
Heterogeneity: Chi ² = Test for overall effect:	8.72, df = Z = 2.50	= 9 (P = (P = 0.0	0.46); l [;] 01)	² = 0%					-4 -2 0	2 2	4
Heterogeneity: Chi ² = Test for overall effect:	8.72, df = Z = 2.50	= 9 (P = (P = 0.0	0.46); l [:])1)	² = 0%					-4 -2 0 Favours [Non-intervention] Fa	2 avours [IF]	4
Heterogeneity: Chi ² = Test for overall effect: B	8.72, df = Z = 2.50 Non-i	= 9 (P = (P = 0.0 nterven	0.46); l [:] 01) tion	² = 0%	IF			Mean Difference	-4 -2 0 Favours [Non-intervention] Fa	2 avours [IF] rence	4
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup	8.72, df = Z = 2.50 Non-i <u>Mean</u>	= 9 (P = (P = 0.0 nterven SD	0.46); l [;])1) tion <u>Total</u>	² = 0% <u>Mean</u>	IF SD	Total	Weight	Mean Difference IV. Fixed, 95% CI	-4 -2 0 Favours [Non-intervention] Fa Mean Differ IV, Fixed, 9	2 avours [IF] rence 95% Cl	4
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013	8.72, df = Z = 2.50 Non-ir <u>Mean</u> 97	= 9 (P = (P = 0.0 nterven <u>SD</u> 8	0.46); i [:] 01) tion <u>Total</u> 16	² = 0% <u>Mean</u> 95	IF SD	Total 16	Weight 3.1%	Mean Difference <u>IV. Fixed, 95% CI</u> 2.00 [-3.54, 7.54]	-4 -2 0 Favours [Non-intervention] Fa Mean Differ IV. Fixed, 9	2 avours [IF] rence 95% Cl	4
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019	8.72, df = Z = 2.50 Non-in <u>Mean</u> 97 88.54	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1	0.46); F 01) tion <u>Total</u> 16 79	² = 0% <u>Mean</u> 95 87.19	IF SD 8 4.88	<u>Total</u> 16 90	<u>Weight</u> 3.1% 41.1%	Mean Difference <u>IV. Fixed. 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86]	-4 -2 0 Favours [Non-intervention] Fa Mean Differ IV. Fixed. 9	2 avours [IF] rence 95% Cl	4
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019	8.72, df = Z = 2.50 Non-ii <u>Mean</u> 97 88.54 88.54	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1	0.46); F 01) tion <u>Total</u> 16 79 79	² = 0% <u>Mean</u> 95 87.19 87.58	IF SD 8 4.88 4.39	<u>Total</u> 16 90 95	Weight 3.1% 41.1% 45.9%	Mean Difference <u>IV. Fixed. 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39]	-4 -2 0 Favours [Non-intervention] Fa	2 avours [IF] rence 05% Cl	4
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Guo 2021	8.72, df = Z = 2.50 Non-ir Mean 97 88.54 88.54 91.6	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1 5.3	0.46); i 01) tion <u>Total</u> 16 79 79 18	2 = 0% Mean 95 87.19 87.58 92.1	IF SD 8 4.88 4.39 10.6	Total 16 90 95 21	Weight 3.1% 41.1% 45.9% 3.5%	Mean Difference <u>IV. Fixed. 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65]	-4 -2 0 Favours [Non-intervention] Fa	2 avours [IF] rence 05% Cl	4
Heterogeneity: Chi ² = Test for overall effect: B <u>Study or Subgroup</u> Bhutani 2013 Cai 2019 Cai 2019 Guo 2021 Kotarsky 2021	8.72, df = Z = 2.50 Non-ir Mean 97 88.54 88.54 91.6 92.3	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1 5.3 9.49	0.46); F 01) tion Total 16 79 79 18 10	<u>Mean</u> 95 87.19 87.58 92.1 92.8	IF SD 8 4.88 4.39 10.6 7.3	<u>Total</u> 16 90 95 21 11	Weight 3.1% 41.1% 45.9% 3.5% 1.8%	Mean Difference <u>IV. Fixed, 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65] -0.50 [-7.79, 6.79]	-4 -2 0 Favours [Non-intervention] Fa	2 avours [IF] rence 95% Cl	- -
Heterogeneity: Chi ² = Test for overall effect: B <u>Study or Subgroup</u> Bhutani 2013 Cai 2019 Cai 2019 Guo 2021 Kotarsky 2021 Lowe 2020	8.72, df = Z = 2.50 Non-ii Mean 97 88.54 88.54 91.6 92.3 105.9	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1 5.3 9.49 10.18	0.46); F 01) tion Total 16 79 79 18 10 24	Mean 95 87.19 87.58 92.1 92.8 104.5	IF 8 4.88 4.39 10.6 7.3 9.92	Total 16 90 95 21 11 22	Weight 3.1% 41.1% 45.9% 3.5% 1.8% 2.8%	Mean Difference <u>IV. Fixed. 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65] -0.50 [-7.79, 6.79] 1.40 [-4.41, 7.21]	A -2 0 Favours [Non-intervention] Fa	2 avours [IF] rence 95% CI	
Heterogeneity: Chi ² = Test for overall effect: B <u>Study or Subgroup</u> Bhutani 2013 Cai 2019 Cai 2019 Guo 2021 Kotarsky 2021 Lowe 2020 Oh 2018	8.72, df = Z = 2.50 Non-ii <u>Mean</u> 97 88.54 88.54 91.6 92.3 105.9 87	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1 5.3 9.49 10.18 8.9	0.46); F 01) tion 16 79 79 18 10 24 10	Mean 95 87.19 87.58 92.1 92.8 104.5 89.4	IF SD 8 4.88 4.39 10.6 7.3 9.92 8.3	Total 16 90 95 21 11 22 13	Weight 3.1% 41.1% 45.9% 3.5% 1.8% 2.8% 1.8%	Mean Difference <u>IV, Fixed, 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65] -0.50 [-7.79, 6.79] 1.40 [-4.41, 7.21] -2.40 [-9.53, 4.73]	-4 -2 0 avours [Non-intervention] Fa Mean Differ IV. Fixed. 9	2 avours [IF] rence 55% CI	
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Guo 2021 Kotarsky 2021 Lowe 2020 Oh 2018 Total (95% CI)	8.72, df = Z = 2.50 <u>Non-ii</u> <u>Mean</u> 97 88.54 88.54 91.6 92.3 105.9 87	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1 5.1 5.3 9.49 10.18 8.9	0.46); F D1) tion Total 16 79 79 18 10 24 10 24 10	Mean 95 87.19 87.58 92.1 92.8 104.5 89.4	IF SD 8 4.88 4.39 10.6 7.3 9.92 8.3	Total 16 90 95 21 11 22 13 268	Weight 3.1% 41.1% 45.9% 3.5% 1.8% 2.8% 1.8% 1.8%	Mean Difference <u>IV. Fixed, 95% CI</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65] -0.50 [-7.79, 6.79] 1.40 [-4.41, 7.21] -2.40 [-9.53, 4.73] 1.02 [0.06, 1.99]	-4 -2 0 Favours [Non-intervention] Fa	2 avours [IF] rence 95% CI	
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Guo 2021 Kotarsky 2021 Lowe 2020 Oh 2018 Total (95% CI) Heterogeneity: Chi ² =	8.72, df = Z = 2.50 Non-ir Mean 97 88.54 88.54 91.6 92.3 105.9 87 1.71, df =	= 9 (P = (P = 0.0 nterven <u>SD</u> 8 5.1 5.1 5.3 9.49 10.18 8.9 = 6 (P =	0.46); F D1) tion Total 16 79 79 18 10 24 10 24 10 236 0.94); F	Mean 95 87.19 87.58 92.1 92.8 104.5 89.4 2 = 0%	IF SD 4.88 4.39 10.6 7.3 9.92 8.3	Total 16 90 95 21 11 22 13 268	Weight 3.1% 41.1% 45.9% 3.5% 1.8% 2.8% 1.8% 1.8%	Mean Difference <u>IV. Fixed, 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65] -0.50 [-7.79, 6.79] 1.40 [-4.41, 7.21] -2.40 [-9.53, 4.73] 1.02 [0.06, 1.99]	-4 -2 0 avours [Non-intervention] Fa Mean Differ IV. Fixed. 9	2 avours [IF] rence 95% CI	-
Heterogeneity: Chi ² = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Guo 2021 Kotarsky 2021 Lowe 2020 Oh 2018 Total (95% CI) Heterogeneity: Chi ² = Test for overall effect:	8.72, df = Z = 2.50 Non-ii 97 88.54 88.54 91.6 92.3 105.9 87 1.71, df = Z = 2.07	= 9 (P = 0.0) nterven $= 0.10$ $= 0.0$ $= 0.0$ $= 0.0$ $= 0.0$ $= 0.0$ $= 0.0$	0.46); F D1) tion Total 16 79 79 18 10 24 10 24 10 236 0.94); F	Mean 95 87.19 87.58 92.1 92.8 104.5 89.4 2² = 0%	IF SD 4.88 4.39 10.6 7.3 9.92 8.3	Total 16 90 95 21 11 22 13 268	Weight 3.1% 41.1% 45.9% 3.5% 1.8% 2.8% 1.8% 1.8%	Mean Difference <u>IV, Fixed, 95% Cl</u> 2.00 [-3.54, 7.54] 1.35 [-0.16, 2.86] 0.96 [-0.47, 2.39] -0.50 [-5.65, 4.65] -0.50 [-7.79, 6.79] 1.40 [-4.41, 7.21] -2.40 [-9.53, 4.73] 1.02 [0.06, 1.99]	-4 -2 0 avours [Non-intervention] Fa Mean Differ IV, Fixed, 9 -10 -5 0	2 avours [IF] rence 95% CI	- - -

weekly TRF reduced WC more effectively than CR (WMD = 3.36, 95% CI: 1.24–6.08, p = 0.003; $I^2 = 38\%$) (**Table 3**). Five studies reported the FM of the weekly TRF and CR subgroup and more reduced FM was discovered in the weekly TRF group (WMD = 2.58, 95% CI: 0.61–4.55, p = 0.01) (**Table 3**). Weekly TRF was also more effective in reducing DBP in participants (WMD = 3.47, 95% CI: (-0.06)–7.00, p = 0.05) (**Table 3**). More detailed physical and biochemical results are recorded in **Table 3**.

Subgroup analysis found that, compared with nonintervention diet and CR, IF had different effects depending on sex. When it comes to women, IF was significantly more effective with highly heterogeneous in reducing FM (WMD = 3.72, 95% CI: 0.56-6.87, p = 0.02; $I^2 = 67\%$) (Table 4). However, no advantage was discovered in any other aspects, such as weight, WC, FM%, FFM, fasting glucose, and insulin level. As for men, the statistical results showed that IF could significantly reduce men's weight and BMI compared with both non-intervention diet and CR, which were supported by 8 and 4 studies, respectively (WMD = 2.16, 95% CI: 0.48–3.85, *p* = 0.01; $I^2 = 29\%$ and WMD = 0.97, 95% CI: 0.23–1.71, p = 0.01; $I^2 =$ 0%, respectively) (Table 4). Moreover, IF also reduced TG levels more effectively in men (WMD = 0.54, 95% CI: 0.22–0.86, p <0.001; $I^2 = 31\%$). More detailed physical and biochemical results are listed in Table 4.

According to the International Obesity Task Force (IOTF), a BMI of 25–30 units in adults is defined as being overweight, while a BMI greater than 30 in an individual is considered to be obese (1). Herein, subgroup analysis was performed specifically on patients with overweight or obesity (BMI ≥ 25 kg/m²) among the included participants. The patients' physical and biochemical parameters of the IF vs. non-intervention diet are recorded in **Table 5**. The results showed that IF could significantly reduce insulin resistance compared with the non-intervention diet (HOMA-IR: WMD = 0.43, 95% CI: 0.04–0.83, p = 0.03). However, there was no significant difference in weight, body composition, and blood lipids. Moreover, the effectiveness of IF and CR was similar in patients with overweight or obesity. The correlated physical and biochemical parameters are recorded in **Table 6**.

Sensitivity Analysis and Publication Bias Analysis

After sensitive analysis, we found that the results were stable. Meanwhile, funnel plots were used to examine publication bias. The funnel plots of all statistical results were displayed to be roughly symmetry, indicating that there was no publication bias.

DISCUSSION

At present, more and more people in the world are suffering from metabolic diseases and obesity (1). Although IF was considered to be related to undesired outcomes, such as gout, arrhythmia, and peptic ulcer (55), it is still widely believed to be able to

	Non-II	nterven	tion		IF			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	I IV, Fixed, 95% CI
Bhutani 2013	43	16	16	41	8	16	0.4%	2.00 [-6.77, 10.77]	
Cai 2019	28.01	3.49	79	27.1	2.52	90	37.6%	0.91 [-0.02, 1.84]	
Cai 2019	28.01	3.49	79	27.65	3.34	95	31.1%	0.36 [-0.66, 1.38]	
Chow 2020	44.7	20.8	9	39.4	16.4	11	0.1%	5.30 [-11.39, 21.99]	
Cienfuegos 2021	41.9	25.04	14	45.6	29.5	16	0.1%	-3.70 [-23.22, 15.82]	
Cienfuegos 2021	41.9	25.04	14	46.1	35.03	19	0.1%	-4.20 [-24.70, 16.30]	· · · · · · · · · · · · · · · · · · ·
Correia 2021	11.1	3.9	12	10.9	3.9	12	3.3%	0.20 [-2.92, 3.32]	
Gabel 2019	35	11.62	15	31	6.63	11	0.7%	4.00 [-3.07, 11.07]	
Guo 2021	21.6	5.2	18	24.9	8.6	21	1.7%	-3.30 [-7.69, 1.09]	
Kotarsky 2021	32	6.32	10	30	6.63	11	1.1%	2.00 [-3.54, 7.54]	
Lowe 2020	30.6	7.1	24	29.8	6.77	22	2.0%	0.80 [-3.21, 4.81]	
Moro 2016	11.05	4.274	17	9.28	2.47	17	5.9%	1.77 [-0.58, 4.12]	<u>+</u>
Oh 2018	22.6	5.7	10	24.3	6.4	13	1.3%	-1.70 [-6.66, 3.26]	
Stote 2007	16.3	3.87	15	14.2	3.87	15	4.2%	2.10 [-0.67, 4.87]	<u>+</u>
Teng 2013	19.1	4.7	28	17.9	3.3	28	7.2%	1.20 [-0.93, 3.33]	+
Tinsley 2017	14.5	3.8	8	17.2	8.3	10	1.0%	-2.70 [-8.48, 3.08]	
Tinsley 2019	19.6	5.24	14	18	5.05	13	2.2%	1.60 [-2.28, 5.48]	-
Total (95% CI)			382			420	100.0%	0.74 [0.17, 1.31]	•
11.1	10 15 df	= 16 (P	= 0.86)	: l² = 0%	, D				
Heterodeneity: Chi ² =	10. I.J. UI		/	,	-				-20 -10 0 10 2
Test for overall effect:	Z = 2.55	(P = 0.0	1)						
Test for overall effect:	Z = 2.55	(P = 0.0	1)						Favours [Non-intervention] Favours [IF]
Test for overall effect:	Z = 2.55	(P = 0.0	1)		IF			Mean Difference	Favours [Non-intervention] Favours [IF]
Test for overall effect: B	Z = 2.55 Non-i Mean	(P = 0.0 interven	ntion	Mean	IF SD	Total	Weight	Mean Difference IV. Fixed, 95% CI	Favours [Non-intervention] Favours [IF] Mean Difference IV. Fixed, 95% CI
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013	Z = 2.55 Non-i <u>Mean</u>	(P = 0.0 interven <u>SD</u>	ntion Total	Mean	IF SD	Total	Weight	Mean Difference IV, Fixed, 95% CI	Favours [Non-intervention] Favours [IF] Mean Difference IV. Fixed, 95% Cl
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019	Z = 2.55 Non-i <u>Mean</u> 49 42 71	(P = 0.0 interven <u>SD</u> 7 67	1) ntion <u>Total</u> 16 79	<u>Mean</u> 50 44 17	IF SD 8 7 79	<u>Total</u> 16 90	Weight 1.7% 9.5%	Mean Difference IV, Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87]	Favours [Non-intervention] Favours [IF] Mean Difference IV. Fixed, 95% CI
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019	Z = 2.55 Non-i <u>Mean</u> 49 42.71 42.71	(P = 0.0 interven <u>SD</u> 8 7.67 7.67	1) Ition Total 16 79 79	<u>Mean</u> 50 44.17	IF SD 8 7.79 7.47	Total 16 90	Weight 1.7% 9.5% 10.1%	Mean Difference IV. Fixed. 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93]	Favours [Non-intervention] Favours [IF] Mean Difference IV. Fixed, 95% CI
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Chow 2020	Z = 2.55 Non-i <u>Mean</u> 49 42.71 42.71	(P = 0.0 interven <u>SD</u> 8 7.67 7.67 7.67	1) Ition Total 16 79 79 9	<u>Mean</u> 50 44.17 44.04	IF SD 8 7.79 7.47	Total 16 90 95 11	Weight 1.7% 9.5% 10.1% 0.9%	Mean Difference IV. Fixed. 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16]	Favours [Non-intervention] Favours [IF] Mean Difference IV. Fixed, 95% CI
Heterogeneity: Chi* = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correcti 2021	Non-i Mean 49 42.71 42.71 51	(P = 0.0 interven <u>SD</u> 8 7.67 7.67 7.8 6 6	1) Ition Total 16 79 79 9 12	Mean 50 44.17 44.04 48.6 61.5	IF SD 8 7.79 7.47 9.9	Total 16 90 95 11	Weight 1.7% 9.5% 10.1% 0.9%	Mean Difference IV, Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] 0.10 [-5.26, 5.66]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chi* = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Cabal 2019	Non-i Mean 49 42.71 42.71 51 61.4	(P = 0.0 interven 8 7.67 7.67 7.8 6.6 11.62	1) Ition Total 16 79 79 9 12 15	Mean 50 44.17 44.04 48.6 61.5	IF SD 8 7.79 7.47 9.9 6.3	Total 16 90 95 11 12	Weight 1.7% 9.5% 10.1% 0.9% 1.9%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [6.32, 10.23]	Favours [Non-intervention] Favours [IF]
Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Cure 2021	Z = 2.55 Non-i <u>Mean</u> 49 42.71 42.71 51 61.4 56 51 2	(P = 0.0 interven <u>SD</u> 8 7.67 7.67 7.8 6.6 11.62	1) tion Total 16 79 79 9 12 15 15	Mean 50 44.17 44.04 48.6 61.5 54	IF SD 7.79 7.47 9.9 6.3 9.95	Total 16 90 95 11 12 11 21	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.00 [-6.32, 7.7 c]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Gabe 2019 Guo 2021 Voteroling 2021	Z = 2.55 Non-i <u>Mean</u> 49 42.71 42.71 51 61.4 56 51.3 40	(P = 0.0 interven 8 7.67 7.67 7.8 6.6 11.62 8.5	1) Ition Total 16 79 79 9 12 15 18 10	Mean 50 44.17 44.04 48.6 61.5 54 49.4	IF <u>SD</u> 8 7.79 7.47 9.9 6.3 9.95 9.9 9.9	Total 16 90 95 11 12 11 21	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.5% 1.7%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.90 [-4.54, 6.54]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chi* = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Mare 2040	Non-i Mean 49 42.71 42.71 51 61.4 56 51.3 48	(P = 0.0 interven 8 7.67 7.67 7.8 6.6 11.62 8.5 6.32	1) tion 16 79 79 9 12 15 18 10 10 10 10 10 10 10 10 10 10	Mean 50 44.17 44.04 48.6 61.5 54 49.4 49.4 70 70 70	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.9 6.63 4.07	Total 16 90 95 11 12 11 21 11	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.5% 1.5% 1.7%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chi* = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Moro 2016 Duble 2027	Non-i Mean 49 42.71 42.71 61.4 51.3 48 74.41	(P = 0.0 interven <u>SD</u> 8 7.67 7.8 6.6 11.62 8.5 6.32 3.59	1) tion Total 16 79 9 9 12 15 18 10 17 17	Mean 50 44.17 44.04 48.6 61.5 54 49.4 47 73.72	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.9 6.63 4.27 4.55	Total 16 90 95 11 12 11 21 11 11 7	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.5% 1.7% 7.3% 1.6% 1.7%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Moro 2016 Stote 2007	Non-i Mean 49 42.71 42.71 61.4 56 51.3 48 74.41 49.4	(P = 0.0 interven <u>SD</u> 8 7.67 7.67 7.8 6.66 11.62 8.5 6.32 3.59 1.55	1) Ition Total 16 79 9 12 15 18 10 17 15 18	Mean 50 44.17 44.04 48.6 61.5 54 49.4 47 73.72 50.9	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.9 6.63 4.27 1.55	Total 16 90 95 11 12 11 21 11 17 15	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.5% 1.7% 7.3% 41.9%	Mean Difference IV, Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39]	Favours [Non-intervention] Favours [IF]
Reterogeneity: Chir = Test for overall effect: B Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Moro 2016 Stote 2007 Teng 2011	Non-i Mean 49 42.71 42.71 61.4 56 51.3 48 74.41 49.4 54.8	(P = 0.0 interven <u>SD</u> 8 7.67 7.68 6.6 11.62 8.5 6.32 3.59 1.55 5.2	1) Ition Total 16 79 9 12 15 18 10 17 15 13	Mean 50 44.17 44.04 48.6 61.5 54 49.4 47 73.72 50.9 52.2	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.9 6.63 4.27 1.55 4.1	Total 16 90 95 11 12 11 21 11 17 15 12	Weight 1.7% 9.5% 10.1% 0.9% 1.7% 1.5% 1.7% 7.3% 41.9% 3.9%	Mean Difference IV. Fixed. 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Moro 2016 Stote 2007 Teng 2013	Non-i Mean 49 42.71 42.71 61.4 56 51.3 48 74.41 49.4 54.8 51.6	(P = 0.0 interven 8 7.67 7.8 6.6 11.62 8.5 6.32 3.59 1.55 5.2 8.8	1) Total Total 16 79 9 12 15 18 10 17 15 13 28	Mean 50 44.17 44.04 48.6 61.5 54 49.4 47 73.72 50.9 52.2 54	IF SD 8 7.79 7.47 9.99 6.3 9.95 9.99 6.63 4.27 1.55 4.1 4.1	Total 16 90 95 11 12 11 21 11 17 15 12 28	Weight 1.7% 9.5% 10.1% 0.9% 1.5% 7.3% 41.9% 3.9% 4.0%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26] -2.40 [-6.00, 1.20]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chir =Test for overall effect:BStudy or SubgroupBhutani 2013Cai 2019Cai 2019Chow 2020Correia 2021Gabel 2019Guo 2021Kotarsky 2021Moro 2016Stote 2007Teng 2011Teng 2013Tinsley 2019	Non-i Mean 49 42.71 42.71 51 61.4 56 51.3 48 74.41 49.4 54.8 51.6 46.3	(P = 0.0 interven 8 7.67 7.67 7.8 6.6 11.62 8.5 6.32 3.59 1.55 5.2 8.8 4.49	1) Total 16 79 9 12 15 18 10 17 15 13 28 9	Mean 50 44.17 48.6 61.5 54 49.4 47 73.72 50.9 52.2 54 46.4	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.95 9.9 6.63 4.27 1.55 4.1 4.1 4.33	Total 16 90 11 12 11 21 11 17 15 12 28 13	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.5% 1.7% 4.19% 3.9% 4.0% 3.6%	Mean Difference IV. Fixed, 95% Cl -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26] -2.40 [-6.00, 1.20] -0.10 [-3.86, 3.66]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chi* =Test for overall effect:BStudy or SubgroupBhutani 2013Cai 2019Cai 2019Chow 2020Correia 2021Gabel 2019Guo 2021Kotarsky 2021Moro 2016Stote 2007Teng 2011Teng 2013Tinsley 2019Trabelsi 2012	Non-i Mean 49 42.71 42.71 61.4 56 51.3 48 74.41 49.4 54.8 51.6 46.3 63.9	(P = 0.0 interven 8 7.67 7.67 7.8 6.6 11.62 8.5 6.32 3.59 1.55 5.5 8.8 4.49 4	1) tion Total 16 79 9 12 15 15 15 15 13 28 9 9 9	Mean 50 44.17 44.04 48.6 61.5 54 49.4 47 73.72 50.9 52.2 54 46.4 63.6	IF 80 7.79 7.47 9.99 6.33 9.95 9.99 6.63 4.27 1.55 4.1 4.1 4.33 2.7	Total 16 90 95 11 12 11 21 11 17 15 12 28 13 10	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 1.5% 1.5% 1.5% 41.9% 3.9% 4.0% 3.6% 5.4%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26] -2.40 [-6.00, 1.20] -0.10 [-3.86, 3.66] 0.30 [-2.80, 3.40]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chir =Test for overall effect:BStudy or SubgroupBhutani 2013Cai 2019Cai 2019Chow 2020Correia 2021Gabel 2019Guo 2021Kotarsky 2021Moro 2016Stote 2007Teng 2011Teng 2013Tinsley 2019Trabelsi 2012Trabelsi 2013	Non-i Mean 49 42.71 42.71 51 61.4 56 51.3 48 74.41 49.4 54.8 51.6 46.3 63.9 68.6	(P = 0.0 interven SD 8 7.67 7.67 7.8 6.6 11.62 8.5 6.32 3.59 1.55 5.2 8.8 4.49 4 2.9	1) Total 16 79 9 12 15 18 10 17 15 13 28 9 8 9 8 8 9 8 8 9 9 8 10 10 10 10 10 10 10 10 10 10	Mean 50 44.17 44.04 48.6 61.5 54 49.4 47 73.72 50.9 52.2 54 46.4 63.6 68	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.99 6.63 9.95 4.27 1.55 4.1 4.23 2.7 3.1	Total 16 90 95 11 12 11 17 15 12 28 13 10 8	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.7% 4.0% 3.9% 4.0% 3.6% 5.4% 6.0%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26] -2.40 [-6.00, 1.20] -0.10 [-3.86, 3.66] 0.30 [-2.80, 3.40] 0.60 [-2.34, 3.54]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chir = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Cai 2019 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Moro 2016 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012 Trabelsi 2013 Total (95% CI)	Non-i Mean 49 42.71 42.71 61.4 56 51.3 48 74.41 49.4 54.8 51.6 46.3 63.9 68.6	(P = 0.0 interven 8 7.67 7.8 6.6 11.62 8.5 6.32 3.59 1.55 5.2 8.8 4.49 4 2.9	1) ition Total 79 9 12 15 18 10 17 15 13 28 9 9 8 337	Mean 50 44.17 48.6 61.5 54 49.4 47 73.72 50.9 52.2 54 46.4 63.6 68	IF SD 8 7.79 7.47 9.9 6.3 9.95 9.9 6.63 4.27 1.55 4.1 4.33 2.7 3.1	Total 16 90 95 11 12 11 11 17 15 12 28 13 10 8 370	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.5% 4.19% 3.9% 4.0% 3.6% 5.4% 6.0% 100.0%	Mean Difference IV. Fixed. 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26] -2.40 [-6.00, 1.20] -0.10 [-3.86, 3.66] 0.30 [-2.80, 3.40] 0.60 [-2.34, 3.54] -0.73 [-1.45, -0.02]	Favours [Non-intervention] Favours [IF]
Heterogeneity: Chi" = Test for overall effect: B Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Chow 2020 Correia 2021 Gabel 2019 Guo 2021 Kotarsky 2021 Moro 2016 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012 Trabelsi 2013 Total (95% CI) Heterogeneity: Chi" =	Non-i Mean 49 42.71 42.71 61.4 56 51.3 48 74.41 49.4 54.8 51.6 46.3 63.9 68.6	(P = 0.0 interven <u>SD</u> 8 7.67 7.67 7.8 6.6 11.62 8.5 6.32 3.59 1.55 5.2 8.8 4.49 4 2.9	1) Total 16 79 9 12 15 13 10 17 15 13 28 9 9 8 337 9 = 0.67	$\begin{array}{c} \text{Mean} \\ 50 \\ 44.17 \\ 44.04 \\ 48.6 \\ 61.5 \\ 54 \\ 49.4 \\ 47 \\ 73.72 \\ 50.9 \\ 52.2 \\ 54 \\ 46.4 \\ 63.6 \\ 68 \end{array}$	IF <u>5D</u> 8 7.79 7.47 9.9 6.63 9.95 9.99 6.63 9.99 6.63 4.27 1.55 4.1 4.23 2.7 3.1	Total 16 90 95 11 12 11 11 17 15 12 28 13 10 8 370	Weight 1.7% 9.5% 10.1% 0.9% 1.9% 0.7% 1.7% 1.7% 4.0% 3.9% 4.0% 3.6% 5.4% 6.0% 100.0%	Mean Difference IV. Fixed, 95% CI -1.00 [-6.54, 4.54] -1.46 [-3.79, 0.87] -1.33 [-3.59, 0.93] 2.40 [-5.36, 10.16] -0.10 [-5.26, 5.06] 2.00 [-6.32, 10.32] 1.90 [-3.87, 7.67] 1.00 [-4.54, 6.54] 0.69 [-1.96, 3.34] -1.50 [-2.61, -0.39] 2.60 [-1.06, 6.26] -2.40 [-6.00, 1.20] -0.10 [-3.86, 3.66] 0.30 [-2.80, 3.40] 0.60 [-2.34, 3.54] -0.73 [-1.45, -0.02]	Favours [Non-intervention] Favours [IF]

reduce weight, relive rheumatoid arthritis, and slow down aging (56, 57), even if they still disagreed on cancer (58, 59). In this study, IF was compared with a non-intervention diet and CR, respectively. In addition, subgroup analysis was conducted based on the pattern of IF, sex, and specific population, which narrowed the population within the overweight or obese population.

In our study, IF was found to have significant benefits in improving outcome indices for weight, FM, insulin, and blood lipids compared to a non-intervention diet. These results were similar to previous studies (6, 56, 60), indicating that IF can result in desirable weight loss and better health. However, there was no difference in fasting blood glucose in participants between the IF group and the non-intervention diet group in this study. It might be due to the fact that the included population in our analysis was mostly non-diabetic individuals, so the basal glucose concentrations were relatively low, resulting in slight fluctuations. As for the results of insulin concentrations and HOMA-IR, IF was proved to be potentially beneficial in relieving insulin resistance. In addition, during the analysis of our study, it was found that in some studies, participants' IF was accompanied by physical exercise. The combination may be more conducive to improving participants' health than IF alone (40). But subjects in both intervention and control groups in the same RCT performed exercise or neither, so the effect of physical activity on this analysis was controllable. In this study, IF was about as effective as CR, only slightly better than CR in reducing WC. Although some researchers believed that, compared with CR, IF had better compliance in participants and was more beneficial in reducing FM (11, 57), other studies showed that long-term compliance of IF was limited due to the



high dropout rate (in contrast to CR, IF had a 38% dropout rate) (61, 62).

As for the comparison between ADF and CR, the subgroup analysis based on the dietary pattern of IF found that ADF had no greater beneficial effects than CR in our study, but other studies showed a difference in superior compliance, FM, and FFM in the ADF group (11, 63). Furthermore, ADF also did not have the burden of chronic poor feeding and other adverse outcomes compared to CR (58). However, some investigators believed that ADF might not be a viable public health intervention because

	Non-i	ntervent	tion		IF		5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Bhutani 2013	102	44	16	86	32	16	3.5%	0.41 [-0.30, 1.11]	
Cai 2019	2.4	1.7	79	2.12	1.9	90	19.0%	0.15 [-0.15, 0.46]	- +
Cai 2019	2.4	1.7	79	2.31	1.75	95	19.5%	0.05 [-0.25, 0.35]	
Chow 2020	87	27	9	106	39	11	2.1%	-0.53 [-1.43, 0.37]	
Gabel 2019	94	30.98	15	97	33.17	11	2.9%	-0.09 [-0.87, 0.69]	
Hirsh 2019	87.1	40.3	12	70.5	34.8	10	2.4%	0.42 [-0.43, 1.27]	
Lowe 2020	136	59.8	24	116.9	57.96	22	5.1%	0.32 [-0.26, 0.90]	
Martens 2020	87	28.14	22	83	27.5	21	4.8%	0.14 [-0.46, 0.74]	
McAllister 2019	89.2	30.9	12	77.7	23.4	10	2.4%	0.40 [-0.45, 1.25]	
Moro 2016	134.58	15.66	17	115.23	11.77	17	3.0%	1.36 [0.61, 2.12]	
Moro 2020	70.38	56.89	8	54.13	20.23	8	1.8%	0.36 [-0.63, 1.35]	
Oh 2018	130.7	86.8	10	120.8	80.6	13	2.6%	0.11 [-0.71, 0.94]	
Schübel 2018	120.5	59.2	52	100.6	47.5	49	11.2%	0.37 [-0.03, 0.76]	
Stote 2007	102.2	29.82	15	93.2	29.82	15	3.3%	0.29 [-0.43, 1.01]	
Teng 2013	1.81	1	28	1.41	0.4	28	6.1%	0.52 [-0.02, 1.05]	
Tinsley 2019	75	48.64	14	93	43.27	13	3.0%	-0.38 [-1.14, 0.38]	
Trabelsi 2012	0.77	0.11	9	0.77	0.13	10	2.1%	0.00 [-0.90, 0.90]	
Trabelsi 2013	0.75	0.11	8	0.75	0.15	8	1.8%	0.00 [-0.98, 0.98]	
Varady 2013	118	73.59	15	87	34.86	15	3.3%	0.52 [-0.21, 1.25]	
Total (95% CI)			444			462	100.0%	0.22 [0.09, 0.35]	•
Heterogeneity: Chi ² =	19.70, df	= 18 (P =	= 0.35);	l² = 9%					
3									
	Non-i	ntervent	tion		IF		;	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Non-i Mean	ntervent SD	tion Total	Mean	IF SD	Total	Weight	Std. Mean Difference IV, Fixed, 95% Cl	Std. Mean Difference IV. Fixed. 95% Cl
<u>Study or Subgroup</u> Bhutani 2013	Non-i Mean 187	ntervent SD 40	tion <u>Total</u> 16	<u>Mean</u> 183	IF <u>SD</u> 44	Total 16	Weight 3.5%	Std. Mean Difference IV. Fixed, 95% Cl 0.09 [-0.60, 0.79]	Std. Mean Difference IV, Fixed, 95% CI
<u>Study or Subgroup</u> Bhutani 2013 Cai 2019	Non-i <u>Mean</u> 187 4.65	ntervent <u>SD</u> 40 1.36	tion <u>Total</u> 16 79	<u>Mean</u> 183 4.37	IF 5D 44 1.53	Total 16 95	Weight 3.5% 19.0%	Std. Mean Difference IV. Fixed, 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49]	Std. Mean Difference IV, Fixed, 95% CI
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019	Non-i <u>Mean</u> 187 4.65 4.65	ntervent SD 40 1.36 1.36	tion Total 16 79 79	<u>Mean</u> 183 4.37 4.15	IF 44 1.53 1.06	Total 16 95 90	Weight 3.5% 19.0% 18.2%	Std. Mean Difference IV. Fixed. 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72]	Std. Mean Difference IV, Fixed, 95% CI
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019	Non-i <u>Mean</u> 187 4.65 4.65 184	ntervent SD 40 1.36 1.36 38.73	tion Total 16 79 79 15	<u>Mean</u> 183 4.37 4.15 184	IF <u>\$D</u> 44 1.53 1.06 43.12	Total 16 95 90 11	Weight 3.5% 19.0% 18.2% 2.8%	Std. Mean Difference IV. Fixed, 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78]	Std. Mean Difference IV. Fixed, 95% CI
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021	Non-i Mean 187 4.65 4.65 184 4.99	ntervent SD 40 1.36 1.36 38.73 0.81	tion Total 16 79 79 15 18	Mean 183 4.37 4.15 184 5.1	IF <u>\$D</u> 44 1.53 1.06 43.12 0.86	Total 16 95 90 11 21	Weight 3.5% 19.0% 18.2% 2.8% 4.3%	Std. Mean Difference IV. Fixed, 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019	Non-i Mean 187 4.65 4.65 184 4.99 196.8	ntervent <u>SD</u> 40 1.36 1.36 38.73 0.81 48.1	tion Total 16 79 79 15 18 12	Mean 183 4.37 4.15 184 5.1 201.1	IF <u>\$D</u> 44 1.53 1.06 43.12 0.86 33.6	Total 16 95 90 11 21 10	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021	Non-i Mean 187 4.65 4.65 184 4.99 196.8 199	ntervent <u>SD</u> 40 1.36 1.36 38.73 0.81 48.1 37.95	tion Total 16 79 79 15 18 12 12	Mean 183 4.37 4.15 184 5.1 201.1 206	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.6 33.17	Total 16 95 90 11 21 10 11	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020	Non-i Mean 187 4.65 4.65 184 4.99 196.8 199 203.5	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82	tion Total 16 79 79 15 18 12 10 24	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1	IF <u>\$D</u> 44 1.53 1.06 43.12 0.86 33.6 33.6 33.17 33.83	Total 16 95 90 11 21 10 11 22	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020	Non-i Mean 187 4.65 4.65 184 4.99 196.8 199 203.5 178	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83	tion Total 16 79 79 15 18 12 10 24 24 22	Mean 183 4.37 4.15 184 5.1 201.1 201.1 206 200.1 189	IF <u>\$D</u> 44 1.53 1.06 43.12 0.86 33.6 33.6 33.17 33.83 41.24	Total 16 95 90 11 21 10 11 22 21	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1	tion Total 16 79 79 15 18 12 10 24 22 22 22	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1	IF <u>\$D</u> 44 1.53 1.06 43.12 0.86 33.6 33.17 33.83 41.24 26.1	Total 16 95 90 11 21 10 11 22 21 10	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3%	Std. Mean Difference IV. Fixed. 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016	Non-i Mean 187 4.65 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 04.02	tion Total 16 79 79 15 18 12 10 24 22 12 12	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.6 33.17 33.83 41.24 26.1 11.2	Total 16 95 90 11 21 10 11 22 21 10 17	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 3.7%	Std. Mean Difference IV. Fixed. 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 Martens 2020 Moro 2016 Moro 2020	Non-i Mean 187 4.65 4.65 184 4.99 1968 199 203.5 178 161.6 197.12 179.38	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08	tion Total 16 79 79 15 18 12 10 24 22 12 12 17 8 5 5	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.37	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.6 33.63 33.83 41.24 26.1 11.2 41.59 22.2	Total 16 95 90 11 21 10 11 22 21 10 17 8	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 1.8%	Std. Mean Difference IV. Fixed. 95% Cl 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 0 5 5	tion Total 16 79 79 15 18 12 10 24 22 12 12 17 8 5 5 5	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 202	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.6 33.6 33.17 33.83 41.24 26.1 11.2 41.59 36.8 20.55 20.	Total 16 95 90 11 21 10 11 22 21 10 17 8 9 49	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 1.8% 1.1%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1	ntervent <u>SD</u> 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53	tion Total 16 79 79 15 18 12 10 24 22 12 12 17 8 52 52 15	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.6 33.6 33.83 41.24 26.1 11.2 41.59 36.8 20.53	Total 16 95 90 11 21 10 11 22 21 10 17 8 49 15	Weight 3.5% 19.0% 18.2% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 5.1% 4.7% 2.3% 1.1% 2.7%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013	Non-i Mean 187 4.65 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 44.1 15.65 31.08 31.3 20.53 1 44.1 1.56 1.57 1	tion Total 16 79 79 15 18 12 10 24 22 12 12 17 8 52 15 24	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.63 33.63 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 20.00	Total 16 95 90 11 21 10 11 22 21 10 17 8 49 15 28 28 20 20 20 20 20 20 20 20 20 20	Weight 3.5% 19.0% 18.2% 2.8% 2.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 1.8% 11.1% 2.7% 6.2%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.17 [-0.36, 0.69] 0.04 [-0.45, 1.07]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013 Tinsley 2019	Non-i Mean 187 4.65 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64 185	ntervent <u>SD</u> 40 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 41.6	tion Total 16 79 79 15 18 12 10 24 22 12 12 12 17 8 52 15 28 14 14	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48 172 4.02	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.67 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 39.66	Total 16 95 90 11 21 10 11 22 10 17 8 49 15 28 13	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 5.1% 4.7% 2.3% 5.1% 4.7% 2.3% 3.7% 6.2% 2.9%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.31 [-0.45, 1.07]	Std. Mean Difference IV. Fixed, 95% CI
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64 185 3.88	ntervent <u>SD</u> 400 1.36 1.37 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 41.16 0.31 0.31	tion <u>Total</u> 16 79 79 15 18 12 10 24 22 12 17 8 52 15 28 14 9 2	Mean 183 4.37 4.15 184 5.11 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48 172 4.08 2.27 4.05 2.27 4.27 2.27 4.27 2.27 4.27 4.27 2.27 4.	IF <u>SD</u> 44 1.53 1.06 43.12 0.86 33.6 33.17 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 39.66 0.28 0.28	Total 16 95 90 11 21 10 11 22 10 17 8 49 15 28 13 10	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 1.8% 1.1% 2.7% 6.2% 2.9% 2.9% 2.9% 2.0%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.31 [-0.45, 1.07] -0.65 [-1.58, 0.28] 0.41 [-0.27, 1.09]	Std. Mean Difference IV. Fixed, 95% CI
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012 Trabelsi 2013 Varady 2013	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64 185 3.88 3.93 202	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 41.16 0.31 0.35 34.86	tion <u>Total</u> 16 79 15 18 12 10 24 22 12 17 8 52 15 28 14 9 8 15 28 15 28 14 9 8	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48 172 4.08 3.87 175	IF SD 44 1.53 1.06 33.6 33.6 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 39.66 0.28 0.35 46.48	Total 16 95 90 11 21 10 101 11 22 11 100 17 8 49 155 28 13 10 8 13 10 8 15 5	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 5.1% 4.7% 2.3% 5.1% 4.7% 2.3% 5.1% 4.7% 2.3% 3.7% 11.1% 2.7% 6.2% 2.9% 2.0% 2.8% 3.1%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.17 [-0.45, 1.07] -0.65 [-1.58, 0.28] 0.16 [-0.82, 1.14] 0.64 [-0.10, 1.38]	Std. Mean Difference IV. Fixed, 95% CI
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012 Trabelsi 2013 Varady 2013	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64 185 3.88 3.93 202	ntervent <u>SD</u> 40 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 41.16 0.31 0.35 34.86	tion <u>Total</u> 16 79 15 18 12 10 24 12 12 10 24 22 12 17 8 52 15 28 14 9 8 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 16 16 16 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 12 10 15 18 18 12 10 15 18 18 12 10 15 18 17 18 18 12 10 15 18 18 18 12 17 18 18 18 19 15 18 18 19 15 15 15 15 15 15 15 15 15 15	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48 172 4.08 3.87 175	IF SD 44 1.53 1.06 43.12 0.86 33.6 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 39.66 0.28 0.35 46.48	Total 16 95 90 11 11 21 10 11 12 21 10 17 8 49 15 28 49 15 28 13 10 8 15 28 13 10 8 15 28 10 10 17 10 10 11 11 22 21 10 10 17 10 10 17 10 17 10 10 17 10 10 17 10 10 17 10 10 17 10 10 10 10 10 10 10 10 10 10	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 1.8% 11.1% 2.7% 6.2% 2.0% 1.8% 3.1%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.17 [-0.36, 0.69] 0.31 [-0.45, 1.07] -0.65 [-1.58, 0.28] 0.16 [-0.82, 1.14] 0.64 [-0.10, 1.38]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012 Trabelsi 2013 Varady 2013	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64 185 3.88 3.93 202	ntervent SD 40 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 41.16 0.31 0.35 34.86 	tion <u>Total</u> 16 79 15 18 12 10 24 22 12 17 8 52 15 28 14 9 8 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 28 15 29 15 16 18 18 12 10 15 18 12 10 15 18 18 19 10 15 18 18 12 10 15 18 18 19 10 10 15 18 18 12 10 15 18 18 19 10 10 15 18 18 18 19 10 10 10 10 10 10 10 10 10 10	Mean 183 4.37 4.15 184 5.1 201.1 206 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48 172 4.08 3.87 175	IF SD 44 1.53 1.06 43.12 0.86 33.6 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 39.66 0.28 0.35 46.48	Total 16 95 900 111 21 10 11 22 11 10 17 8 49 15 28 13 10 8 15 28 13 10 8 8 45	Weight 3.5% 19.0% 18.2% 2.8% 4.3% 2.4% 2.3% 5.1% 4.7% 2.3% 3.7% 1.8% 11.1% 2.7% 6.2% 2.0% 1.8% 3.1% 100.0%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.17 [-0.45, 1.07] -0.65 [-1.58, 0.28] 0.16 [-0.82, 1.14] 0.64 [-0.10, 1.38] 0.13 [0.00, 0.26]	Std. Mean Difference
Study or Subgroup Bhutani 2013 Cai 2019 Gabel 2019 Guo 2021 Hirsh 2019 Kotarsky 2021 Lowe 2020 Martens 2020 McAllister 2019 Moro 2016 Moro 2020 Schübel 2018 Stote 2007 Teng 2013 Tinsley 2019 Trabelsi 2012 Trabelsi 2013 Varady 2013 Total (95% CI)	Non-i Mean 187 4.65 184 4.99 196.8 199 203.5 178 161.6 197.12 179.38 191.1 191 5.64 185 3.88 3.93 202 24.26, df =	ntervent SD 40 1.36 1.36 38.73 0.81 48.1 37.95 117.82 32.83 44.1 15.66 31.08 31.3 20.53 1 41.16 0.35 34.86 = 18 (P = 5)	tion <u>Total</u> 16 79 15 18 12 10 24 22 12 17 8 52 15 28 14 9 8 15 28 14 9 8 15 28 15 15 15 15 15 15 15 15 15 15	Mean 183 4.37 4.15 184 5.1 200.1 189 144.1 191.37 181.38 185.1 216.5 5.48 172 4.08 3.87 175 1/2 260 1/2 1/2 1/2 1/2 1/2 1/2 1/2 1/2	IF SD 44 1.53 1.06 33.6 33.17 33.83 41.24 26.1 11.2 41.59 36.8 20.53 0.9 39.66 0.28 0.35 46.48	Total 16 95 900 11 21 10 11 22 21 10 17 7 8 49 15 28 49 15 28 13 10 8 8 15 470	Weight 3.5% 19.0% 18.2% 2.3% 2.4% 2.3% 5.1% 4.7% 2.3% 11.1% 2.7% 6.2% 2.9% 2.0% 3.1% 100.0%	Std. Mean Difference IV. Fixed, 95% CI 0.09 [-0.60, 0.79] 0.19 [-0.11, 0.49] 0.41 [0.11, 0.72] 0.00 [-0.78, 0.78] -0.13 [-0.76, 0.50] -0.10 [-0.94, 0.74] -0.19 [-1.05, 0.67] 0.04 [-0.54, 0.62] -0.29 [-0.89, 0.31] 0.45 [-0.40, 1.31] 0.41 [-0.27, 1.09] -0.05 [-1.03, 0.93] 0.17 [-0.22, 0.57] -1.21 [-2.00, -0.42] 0.17 [-0.45, 1.07] 0.65 [-1.58, 0.28] 0.16 [-0.82, 1.14] 0.64 [-0.10, 1.38] 0.13 [0.00, 0.26]	Std. Mean Difference IV. Fixed, 95% CI

of considerably and continuously reported hunger by Patterson et al. (8, 64). It was believed that hunger affected participants' enthusiasm and adherence to fasting (64). In addition, compared to ADF, weekly TRF exerted significant advantages on the regulation of WC, FM, and DBP. Another meta-analysis also reported that besides weight, DBP, and insulin regulation, TRF was also more effective in reducing FFM (12).

In addition, IF might play a small role in women because FM was the only parameter that was found to be significantly reduced after IF in women. Comparatively, IF was found to have significantly reduced weight and TG in men. The reason for the difference based on sex was currently not clear. It may be due to the differences in energy intake between men and women, but this study was not able to qualitatively compare the energy intake between men and women because of different RCT settings with different energy limits. Besides, we also assumed that it might be related to the sex-depending fat distribution and sex hormones (65). Estrogen was considered to be able to suppress appetite and reduce the accumulation of belly fat, while androgen promoted food intake. However, research on the relationship between IF and human sex hormones is lacking. Moreover, our subgroup analysis against patients with overweight or obesity showed that IF could not provide more benefit to this particular population. This was at odds with previous studies by researchers

TABLE 2 Physical and biochemical parameters of IF vs. (CR
---	----

	No. of studies	SMD/WMD	95%CI	p	l² (%)	Effect-model
Weight	6	2.08	-0.61-4.77	0.13	22	Fixed
BMI	11	0.35	-0.64-1.34	0.49	57	Random
WC	10	2.29	0.57-4.01	0.009	35	Fixed
FM(kg)	12	1.96	-0.34-4.27	0.09	72	Random
FM%	8	0.77	-0.62-2.16	0.28	5	Fixed
FFM(kg)	10	0.65	-0.51-1.81	0.27	0	Fixed
SBP	9	1.75	-0.41-3.90	0.11	45	Fixed
DBP	9	1.06	-0.53-2.65	0.19	0	Fixed
Glucose	12	-0.01	-0.16-0.14	0.87	22	Fixed
Insulin	10	0.07	-0.09-0.22	0.40	44	Fixed
HOMA-IR	7	0.00	-0.31-0.32	0.99	54	Random
TG	10	0.03	-0.14-0.19	0.76	20	Fixed
TC	10	0.08	-0.09-0.24	0.35	0	Fixed
LDL	9	0.06	-0.11-0.23	0.49	0	Fixed

CR, calorie restriction; IF, intermittent fasting; BMI: body mass index; WC, waist circumference; FM, fat mass; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment insulin resistance; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; SMD, standard mean difference; WMD, weighted mean difference; CI, confidence interval. SMD: glucose, insulin, TG, TC, and LDL; WMD: weight, BMI, WC, FM (kg), FM%, FFM (kg), SBP, DBP, and HOMA-IR. Bold indicates statistically significant differences (P < 0.05).

who believed that IF is functional in regulating blood pressure, TC, and TG, especially more than CR does, in patients with overweight or obesity (30, 66). One theory we speculated was the insufficient quantity of included studies, another might be that the intervention time was relatively short in our study, which was a median follow-up of only 3 months, thus no appearance of IF efficacy was observed.

In many ways, the effects of IF and CR overlapped significantly (55). The essence of both IF and CR was to reduce energy intake. The difference was that CR maintained a normal eating frequency, while IF was no or small amounts of energy intake during fasting (58). Although most of the included studies in this study did not perform energy intake interventions during nonfasting periods, there were still some studies that restricted energy intake during feeding periods, and certain eating patterns of IF also shaped a certain degree of energy restriction (18, 48). Thus, while IF was discovered to be superior to the non-intervention diet in this study, it was unclear whether time restriction or energy restriction played a greater role. In contrast, in our study, IF and CR had few differences in their effects on participants, while the previous studies showed that CR could promote weight loss, relieve insulin resistance, improve insulin sensitivity, lower TG and TC, and elevate HDL (67). Although IF did not restrict calories in some of the included studies (36), it is suspected in this study that CR may be dominant as time restriction did not seem to play a role.

Some researchers suggested that weight loss after CR was due to the adaptation to metabolically induced reductions in FM and FFM (67, 68). The weight loss resulting from IF was also due to the reduction of FM and FFM. However, the difference was that IF, in addition to metabolic adaptations, consumed the stored hepatic glycogen 10–12 h after fasting and then generated massive ketone bodies through the oxidation of fatty acids in adipose tissue, which would be used as the energy source of the whole body (69, 70). Therefore, an increase in blood ketones was found after IF, but not after CR alone (55). Unfortunately, this investigation was not included in this study. The decrease in blood TG might also be due to the oxidative breakdown of fat and the restriction of fat intake (67). Although previous studies attributed weight loss after IF and CR to the reduction of FM and FFM (67, 70), it was an important discovery in this study that IF preserved FFM better. This finding contributes to further recognition of IF, which is that IF does not damage lean tissue, dissipating the concern of IF being the potential cause of osteoporosis and sarcopenia (12).

One of the neuroendocrine mechanisms by which CR mediated was that CR could cause decreased levels of anabolic hormones including insulin, leptin, estrogen, and testosterone (71). CR in combination with weight loss can further improve insulin sensitivity, which might lead to decreased insulin secretion (72). In addition to the above possible mechanisms, IF might also act on the central nervous system via ketone bodies generated by fat metabolism. This process enhances the effect of leptin and insulin on the central nervous system, which normally regulates food intake and insulin sensitivity as well as resistance (62). Herein, insulin levels decreased, and insulin resistance was relieved after IF with no significance. Both CR and IF lowered TC (67). This is probably due to the mechanistic target of the rapamycin (mTOR) pathway (55, 71). IF might lower TC by inhibiting TC production via suppressing this pathway. Since this pathway could also be activated by CR, it is reasonable to discover no difference in TC concentrations between the two intervention groups.

Researchers have proposed three possible mechanisms for IF, such as circadian rhythms, gastrointestinal microbiota, and modifiable lifestyle behaviors (8). Some researchers argued that the human body clock was affected by, but not limited to, metabolic hormones, nutrients, intracellular metabolism, and

TABLE 3 | Physical and biochemical parameters of ADF vs. CR and TRF (week) vs. CR.

	No. of studies	SMD/ WMD	95%CI	p	l ² (%)	Effect-model
ADF vs. C	R					
Weight	6	2.09	-2.91-7.10	0.41	63	Random
BMI	5	0.66	-0.24-1.57	0.15	45	Fixed
WC	3	1.37	-1.34-4.08	0.32	28	Fixed
FM(kg)	6	2.80	-0.74-6.34	0.12	78	Random
FM%	3	1.11	-1.00-3.23	0.30	38	Fixed
FFM(kg)	4	0.23	-1.64-2.11	0.81	0	Fixed
SBP	3	4.34	-5.83-14.50	0.40	79	Random
DBP	3	-0.03	-2.47-2.41	0.98	0	Fixed
Glucose	4	0.10	-0.32-0.53	0.63	56	Random
Insulin	4	0.25	-0.23-0.73	0.31	65	Random
TG	4	-0.01	-0.25-0.24	0.96	28	Fixed
TC	4	0.04	-0.21-0.28	0.78	0	Fixed
LDL	4	0.05	-0.19-0.30	0.68	0	Fixed
HDL	4	-0.08	-0.59-0.44	0.77	71	Random
TRF(weel	k) vs. CR					
Weight	8	2.41	-0.33-5.14	0.08	42	Fixed
BMI	4	0.66	-0.91-2.22	0.41	51	Random
WC	6	3.66	1.24-6.08	0.003	38	Fixed
FM(kg)	5	2.58	0.61-4.55	0.01	45	Fixed
FM%	4	1.42	-0.68-3.53	0.18	0	Fixed
FFM(kg)	5	1.27	-0.29-2.82	0.11	2	Fixed
SBP	4	3.19	-1.26-7.63	0.16	0	Fixed
DBP	4	3.47	-0.06-7.00	0.05	0	Fixed
Glucose	6	-0.08	-0.29-0.14	0.49	14	Fixed
Insulin	4	0.05	-0.34-0.43	0.81	59	Random
TG	5	0.11	-0.14-0.36	0.39	33	Fixed
ТС	4	0.13	-0.13-0.40	0.33	0	Fixed
LDL	4	0.07	-0.20-0.33	0.63	0	Fixed
HDL	4	-0.07	-0.34-0.19	0.60	0	Fixed

CR, calorie restriction; ADF, alternate-day fasting; TRF, time-restricted feeding; BMI: body mass index; WC, waist circumference; FM, fat mass; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SMD, standard mean difference; WMD, weighted mean difference; CI, confidence interval. SMD: glucose, insulin, TG, TC, LDL, and HDL; WMD: weight, BMI, WC, FM (kg), FM%, FFM (kg), SBP, and DBP. Bold indicates statistically significant differences (P < 0.05).

intestinal flora (73). The human circadian rhythms regulate eating, sleep, hormonal and physiological processes, coordinated metabolism, and energetics. Certain patterns of IF might affect the body clock by revising the time humans eat, thus realigning metabolism and energy allocation to ensure human health (8). Sutton's study of daily TRF, and 6-h daily eating during 5 weeks, showed that TRF improved cardio-metabolic health (74). Unfortunately, due to the limited number of studies, we were unable to conduct a comparative analysis between daily TRF and CR or a non-intervention diet. In contrast, the feeding window of the non-fasting period for weekly TRF and ADF was not addressed in the viewed RCTs (45, 75), so it was unknown whether circadian rhythms play a role in these two patterns of $\ensuremath{\mathsf{TABLE 4}}\xspace$ | Physical and biochemical parameters of IF vs. non-intervention diet/CR in women and men.

	No. of studies	SMD/ WMD	95%CI	p	l² (%)	Effect-model
Female						
Weight	6	2.08	-0.61-4.77	0.13	22	Fixed
WC	5	1.80	-1.53-5.13	0.29	50	Random
FM(kg)	5	3.72	0.56–6.87	0.02	67	Random
FM%	3	0.68	-1.45-2.80	0.53	0	Fixed
FFM(kg)	4	1.10	-0.37-2.57	0.14	0	Fixed
Glucose	3	-0.00	-0.17-0.17	1.00	0	Fixed
Insulin	3	0.92	-0.21-2.06	0.11	0	Fixed
Male						
Weight	8	2.16	0.48–3.85	0.01	29	Fixed
BMI	4	0.97	0.23-1.71	0.01	0	Fixed
FM(kg)	4	0.98	-0.38-2.35	0.16	0	Fixed
FM%	7	0.40	-0.12-0.92	0.14	0	Fixed
FFM(kg)	6	0.37	-0.98-1.72	0.59	0	Fixed
Glucose	6	0.09	-0.21-0.40	0.55	0	Fixed
TG	6	0.54	0.22-0.86	<0.001	31	Fixed
ТС	6	0.15	-0.16-0.45	0.36	0	Fixed
LDL	5	0.17	-0.16-0.49	0.32	19	Fixed
HDL	5	-0.09	-0.41-0.24	0.60	0	Fixed

CR, calorie restriction; IF, intermittent fasting; BMI: body mass index; WC, waist circumference; FM, fat mass; FFM, fat-free mass; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SMD, standard mean difference; WMD, weighted mean difference; CI, confidence interval. SMD: glucose (men), TG, TC, and LDL; WMD: weight, BMI, WC, FM (kg), FM%, FFM (kg), glucose (women), and insulin.

Bold indicates statistically significant differences (P < 0.05).

TABLE 5 | Physical and biochemical parameters of IF vs. non-intervention diet in patients with BMI ≥ 25 kg/m².

	No. of studies	WMD	95%CI	p	l² (%)	Effect-model
Weight	6	3.42	-0.77-7.61	0.11	0	Fixed
BMI	3	1.39	-0.12-2.90	0.07	0	Fixed
FM(kg)	5	2.52	-1.22-6.26	0.19	0	Fixed
FFM(kg)	4	0.72	-2.51-3.94	0.66	0	Fixed
SBP	5	1.63	-3.12-6.37	0.50	0	Fixed
DBP	5	0.65	-2.52-3.81	0.69	7	Fixed
Glucose	4	0.33	-2.36-3.02	0.81	39	Fixed
Insulin	6	1.46	-0.36-3.29	0.12	0	Fixed
HOMA-IR	5	0.43	0.04–0.83	0.03	0	Fixed
TG	5	7.70	-3.85-19.26	0.19	33	Fixed
TC	5	2.81	-7.36-12.99	0.59	0	Fixed
LDL	5	4.73	-3.32-12.79	0.25	0	Fixed
HDL	6	0.40	-3.06-3.86	0.82	49	Fixed

IF, intermittent fasting; BMI: body mass index; FM, fat mass; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostasis model assessment insulin resistance; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; WMD, weighted mean difference; CI, confidence interval.

Bold indicates statistically significant differences (P < 0.05).

TABLE 6 | Physical and biochemical parameters of IF vs. CR in patients with BMI \geq 25 kg/m².

	No. of studies	SMD/WM	D 95%CI	р	l² (%)	Effect-model
Weight	13	0.25	-2.88-3.37	0.88	52	Random
BMI	11	0.35	-0.64-1.34	0.49	57	Random
WC	7	1.58	-0.60-3.76	0.16	36	Fixed
FM(kg)	9	1.61	-1.32-4.54	0.28	74	Random
FM%	6	0.54	-1.13-2.21	0.53	26	Fixed
FFM(kg)	8	-0.13	-1.70-1.44	0.87	0	Fixed
SBP	9	1.75	-0.41-3.90	0.11	45	Fixed
DBP	9	1.06	-0.53-2.65	0.19	0	Fixed
Glucose	10	0.05	-0.12-0.23	0.55	16	Fixed
Insulin	9	0.02	-0.15-0.19	0.82	42	Fixed
HOMA-IR	6	-0.18	-0.39-0.03	0.10	46	Fixed
TG	10	0.03	-0.14-0.19	0.76	20	Fixed
TC	9	0.08	-0.09-0.25	0.35	0	Fixed
LDL	9	0.06	-0.11-0.23	0.49	0	Fixed
HDL	9	0.02	-0.15-0.19	0.79	42	Fixed

CR, calorie restriction; IF, intermittent fasting; BMI: body mass index; WC, waist circumference; FM, fat mass; FFM, fat-free mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IP, homeostasis model assessment insulin resistance; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SMD, standard mean difference; WMD, weighted mean difference; CI, confidence interval. SMD: glucose, insulin, TG, TC, LDL, and HDL; WMD: weight, BMI, WC, FM (kg), FM%, FFM (kg), SBP, DBP, and HOMA-IR.

IF. An irregular and inappropriate diet might lead to metabolic disorders and other adverse consequences (73). Although current IF was actually accompanied by energy restriction, it was undeniable that IF limited daytime hours of feeding, which might contribute to improved parameters (8). Both the two other hypotheses, such as gastrointestinal microbiota and modifiable lifestyle behaviors, lacked human clinical trials and could not be confirmed in relation to IF in this study.

This study is a systematic meta-analysis based on RCTs of IF, and it is multi-angle and relatively comprehensive compared with previous meta-analyses (76–78). This study compared IF with CR and non-intervention diets separately, and subgroup analysis was performed according to the patterns of IF and population characteristics. However, there are still considerable limitations in this study. First, this study mixes various patterns of IF, which might reduce the reliability and interpretability. Second, part of

REFERENCES

- Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* (2014) 384:766–81. doi: 10.1016/S0140-6736(14)60460-8
- Qasim A, Turcotte M, de Souza RJ, Samaan MC, Champredon D, Dushoff J, et al. On the origin of obesity: identifying the biological, environmental and cultural drivers of genetic risk among human populations. *Obes Rev.* (2018) 19:121–49. doi: 10.1111/obr.12625

the outcomes, such as hip circumference and waist-to-hip ratio, could not be analyzed in this study due to insufficient data, which might produce publication bias. Moreover, although subgroup analysis was conducted, the role of various factors such as the long-term effect of IF was not thoroughly analyzed in detail due to the limited number of studies. Finally, only studies that were published in English were included, which also may bring publication bias.

CONCLUSION

In conclusion, our analysis revealed that IF was more beneficial in improving body weight, WC, and FM without affecting lean mass compared to a non-intervention diet. IF could also improve the condition of insulin resistance and blood lipid compared with non-intervention diets, but act similar to CR. Different patterns of IF had different effects on metabolism. Moreover, the effects of IF were not uniform across women and men or in the overweight or obese population. More and larger multicentered studies are needed to evaluate IF, while this study may lay a foundation for follow-up research to examine more extensively the reliable effects of IF.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

HL and LG designed the research process. LG and RF searched the database for corresponding articles and drafted the metaanalysis. JH extracted useful information from the articles above. HN used statistical software for analysis. KY polished this article. All the authors had read and approved the manuscript and ensured that this was the case.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022. 871682/full#supplementary-material

- Headland ML, Clifton PM, Keogh JB. Effect of intermittent compared to continuous energy restriction on weight loss and weight maintenance after 12 months in healthy overweight or obese adults. *Int J Obes (Lond)*. (2019) 43:2028–36. doi: 10.1038/s41366-018-0247-2
- Ahmed N, Farooq J, Siddiqi HS, Meo SA, Kulsoom B, Laghari AH et al. Impact of intermittent fasting on lipid profile-a quasi-randomized clinical trial. *Front Nutr.* (2020) 7:596787. doi: 10.3389/fnut.2020.596787
- Sainsbury A, Wood RE, Seimon RV, Hills AP, King NA, Gibson AA et al. Rationale for novel intermittent dieting strategies to attenuate adaptive responses to energy restriction. *Obes Rev.* (2018) 19:47–60. doi: 10.1111/obr.12787

- Martínez-Rodríguez A, Rubio-Arias JA, García-De Frutos JM, Vicente-Martínez M, Gunnarsson TP. Effect of high-intensity interval
- training and intermittent fasting on body composition and physical performance in active women. *Int J Environ Res Public Health.* (2021) 18. doi: 10.3390/ijerph18126431
- Correia JM, Santos I, Minderico C, Pezarat-Correia P, Schoenfeld BJ, Mendonca GV. Effects of time-restricted feeding on supramaximal exercise performance and body composition: a randomized and counterbalanced crossover study in healthy men. *Int J Environ Res Public Health*. (2021) 18. doi: 10.21203/rs.3.rs-612812/v1
- Patterson RE, Laughlin GA, LaCroix AZ, Hartman SJ, Natarajan L, Senger CM, et al. Intermittent Fasting and Human Metabolic Health. J Acad Nutr Diet. (2015) 115:1203–12. doi: 10.1016/j.jand.2015.02.018
- Trabelsi K, el Abed K, Stannard SR, Jammoussi K, Zeghal KM, Hakim A. Effects of fed- versus fasted-state aerobic training during Ramadan on body composition and some metabolic parameters in physically active men. *Int J Sport Nutr Exerc Metab.* (2012) 22:11–8. doi: 10.1123/ijsnem.22.1.11
- O'Connor SG, Boyd P, Bailey CP, Shams-White MM, Agurs-Collins T, Hall K, et al. Perspective: time-restricted eating compared with caloric restriction: potential facilitators and barriers of long-term weight loss maintenance. *Adv Nutr.* (2021) 12:325–33. doi: 10.1093/advances/nmaa168
- Alhamdan BA, Garcia-Alvarez A, Alzahrnai AH, Karanxha J, Stretchberry DR, Contrera KJ, et al. Alternate-day versus daily energy restriction diets: which is more effective for weight loss? A systematic review and meta-analysis. *Obes Sci Pract.* (2016) 2:293–302. doi: 10.1002/osp4.52
- 12. Chen JH, Lu LW, Ge Q, Feng D, Yu J, Liu B, et al. Missing puzzle pieces of time-restricted-eating (TRE) as a long-term weight-loss strategy in overweight and obese people? A systematic review and meta-analysis of randomized controlled trials. *Crit Rev Food Sci Nutr.* (2021) 9:1–17. doi: 10.1080/10408398.2021.1974335
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ*. (2009) 339:b2700. doi: 10.1136/bmj.b2700
- Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928
- van Aert RCM, Wicherts JM, van Assen M. Publication bias examined in meta-analyses from psychology and medicine: A meta-meta-analysis. *PLoS* ONE. (2019) 14:e0215052. doi: 10.1371/journal.pone.0215052
- Antoni R, Johnston KL, Collins AL, Robertson MD. Intermittent v. continuous energy restriction: differential effects on postprandial glucose and lipid metabolism following matched weight loss in overweight/obese participants. *Br J Nutr.* (2018) 119:507–16. doi: 10.1017/S0007114517003890
- Beaulieu K, Casanova N, Oustric P, Turicchi J, Gibbons C, Hopkins M et al. Matched weight loss through intermittent or continuous energy restriction does not lead to compensatory increases in appetite and eating behavior in a randomized controlled trial in women with overweight and obesity. *J Nutr.* (2020) 150:623–33. doi: 10.1093/jn/nxz296
- Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Varady KA. Alternate day fasting and endurance exercise combine to reduce body weight and favorably alter plasma lipids in obese humans. *Obesity (Silver Spring)*. (2013) 21:1370–9. doi: 10.1002/oby.20353
- Bowen J, Brindal E, James-Martin G, Noakes M. Randomized trial of a high protein, partial meal replacement program with or without alternate day fasting: similar effects on weight loss, retention status, nutritional, metabolic, and behavioral outcomes. *Nutrients*. (2018) 10. doi: 10.3390/nu100 91145
- Cai H, Qin YL, Shi ZY, Chen JH, Zeng MJ, Zhou W et al. Effects of alternateday fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. *BMC Gastroenterol.* (2019) 19:219. doi: 10.1186/s12876-019-1132-8
- Carlson O, Martin B, Stote KS, Golden E, Maudsley S, Najjar SS et al. Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women. *Metabolism.* (2007) 56:1729–34. doi: 10.1016/j.metabol.2007.07.018
- 22. Catenacci VA, Pan Z, Ostendorf D, Brannon S, Gozansky WS, Mattson MP et al. A randomized pilot study comparing zero-calorie alternate-day fasting

to daily caloric restriction in adults with obesity. *Obesity (Silver Spring).* (2016) 24:1874–83. doi: 10.1002/oby.21581

- Chow LS, Manoogian ENC, Alvear A, Fleischer JG, Thor H, Dietsche K et al. Time-restricted eating effects on body composition and metabolic measures in humans who are overweight: a feasibility study. *Obesity (Silver Spring).* (2020) 28:860–9. doi: 10.1002/oby.22756
- 24. Cienfuegos S, Gabel K, Kalam F, Ezpeleta M, Pavlou V, Lin S, et al. The effect of 4-h versus 6-h time restricted feeding on sleep quality, duration, insomnia severity and obstructive sleep apnea in adults with obesity. *Nutr Health*. (2022) 28:5–11. doi: 10.1177/02601060211002347
- 25. Conley M, Le Fevre L, Haywood C, Proietto J. Is two days of intermittent energy restriction per week a feasible weight loss approach in obese males? A randomised pilot study. *Nutr Diet.* (2018) 75:65–72. doi: 10.1111/1747-0080.12372
- Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. *Diabet Med.* (2018) 35:588–94. doi: 10.1111/dme.13595
- Coutinho SR, Halset EH, Gåsbakk S, Rehfeld JF, Kulseng B, Truby H et al. Compensatory mechanisms activated with intermittent energy restriction: a randomized control trial. *Clin Nutr.* (2018) 37:815–23. doi: 10.1016/j.clnu.2017.04.002
- Gabel K, Kroeger CM, Trepanowski JF, Hoddy KK, Cienfuegos S, Kalam F et al. Differential effects of alternate-day fasting versus daily calorie restriction on insulin resistance. *Obesity (Silver Spring)*. (2019) 27:1443–50. doi: 10.1002/oby.22564
- Guo Y, Luo S, Ye Y, Yin S, Fan J, Xia M. Intermittent fasting improves cardiometabolic risk factors and alters gut microbiota in metabolic syndrome patients. *J Clin Endocrinol Metab.* (2021) 106:64–79. doi: 10.1210/clinem/dgaa644
- 30. Harvie MN, Pegington M, Mattson MP, Frystyk J, Dillon B, Evans G et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. *Int J Obes (Lond)*. (2011) 35:714–27. doi: 10.1038/ijo.2010.171
- 31. Harvie M, Wright C, Pegington M, McMullan D, Mitchell E, Martin B et al. The effect of intermittent energy and carbohydrate restriction v. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. Br J Nutr. (2013) 110:1534–47. doi: 10.1017/S0007114513000792
- Hirsh SP, Pons M, Joyal SV, Swick AG. Avoiding holiday seasonal weight gain with nutrient-supported intermittent energy restriction: a pilot study. J Nutr Sci. (2019) 8:e11. doi: 10.1017/jns.2019.8
- 33. Kotarsky CJ, Johnson NR, Mahoney SJ, Mitchell SL, Schimek RL, Stastny SN et al. Time-restricted eating and concurrent exercise training reduces fat mass and increases lean mass in overweight and obese adults. *Physiol Rep.* (2021) 9:e14868. doi: 10.14814/phy2.14868
- Kunduraci YE, Ozbek H. Does the Energy restriction intermittent fasting diet alleviate metabolic syndrome biomarkers? A randomized controlled trial. *Nutrients*. (2020) 12. doi: 10.3390/nu12103213
- 35. Lowe DA, Wu N, Rohdin-Bibby L, Moore AH, Kelly N, Liu YE, et al. Effects of time-restricted eating on weight loss and other metabolic parameters in women and men with overweight and obesity: the treat randomized clinical trial. *JAMA Intern Med.* (2020) 180:1491–9. doi: 10.1001/jamainternmed.2020.4153
- Martens CR, Rossman MJ, Mazzo MR, Jankowski LR, Nagy EE, Denman BA et al. Short-term time-restricted feeding is safe and feasible in nonobese healthy midlife and older adults. *Geroscience*. (2020) 42:667–86. doi: 10.1007/s11357-020-00156-6
- McAllister MJ, Pigg BL, Renteria LI, Waldman HS. Time-restricted feeding improves markers of cardiometabolic health in physically active college-age men: a 4-week randomized pre-post pilot study. *Nutr Res.* (2020) 75:32–43. doi: 10.1016/j.nutres.2019.12.001
- 38. Moro T, Tinsley G, Bianco A, Marcolin G, Pacelli QF, Battaglia G et al. Effects of eight weeks of time-restricted feeding (16/8) on basal metabolism, maximal strength, body composition, inflammation, and cardiovascular risk factors in resistance-trained males. J Transl Med. (2016) 14:290. doi: 10.1186/s12967-016-1044-0
- 39. Moro T, Tinsley G, Longo G, Grigoletto D, Bianco A, Ferraris C et al. Time-restricted eating effects on performance, immune function, and body

composition in elite cyclists: a randomized controlled trial. J Int Soc Sports Nutr. (2020) 17:65. doi: 10.1186/s12970-020-00396-z

- 40. Oh M, Kim S, An KY, Min J, Yang HI, Lee J et al. Effects of alternate day calorie restriction and exercise on cardio-metabolic risk factors in overweight and obese adults: an exploratory randomized controlled study. *BMC Public Health.* (2018) 18:1124. doi: 10.1186/s12889-018-6009-1
- Panizza CE, Lim U, Yonemori KM, Cassel KD, Wilkens LR, Harvie MN, et al. Effects of intermittent energy restriction combined with a mediterranean diet on reducing visceral adiposity: a randomized active comparator pilot study. *Nutrients*. (2019) 11. doi: 10.3390/nu11061386
- 42. Parvaresh A, Razavi R, Abbasi B, Yaghoobloo K, Hassanzadeh A, Mohammadifard N et al. Modified alternate-day fasting vs. calorie restriction in the treatment of patients with metabolic syndrome: A randomized clinical trial Complement. *Ther Med.* (2019) 47:102187. doi: 10.1016/j.ctim.2019.08.021
- Pureza I, Melo ISV, Macena ML, Praxedes DRS, Vasconcelos LGL, Silva-Júnior AE et al. Acute effects of time-restricted feeding in low-income women with obesity placed on hypoenergetic diets: Randomized trial. *Nutrition*. (2020) 77:110796. doi: 10.1016/j.nut.2020.110796
- 44. de Oliveira Maranhão Pureza IR, da Silva Junior AE, Silva Praxedes DR, Lessa Vasconcelos LG, de Lima Macena M, Vieira de Melo IS, et al. Effects of time-restricted feeding on body weight, body composition and vital signs in low-income women with obesity: A 12-month randomized clinical trial. *Clin Nutr.* (2021) 40:759–66. doi: 10.1016/j.clnu.2020.06.036
- 45. Razavi R, Parvaresh A, Abbasi B, Yaghoobloo K, Hassanzadeh A, Mohammadifard N et al. The alternate-day fasting diet is a more effective approach than a calorie restriction diet on weight loss and hs-CRP levels. *Int J Vitam Nutr Res.* (2021) 91:242–50. doi: 10.1024/0300-9831/a000623
- 46. Schübel R, Nattenmüller J, Sookthai D, Nonnenmacher T, Graf ME, Riedl L et al. Effects of intermittent and continuous calorie restriction on body weight and metabolism over 50 wk: a randomized controlled trial. *Am J Clin Nutr.* (2018) 108:933–45. doi: 10.1093/ajcn/nqy196
- 47. Stote KS, Baer DJ, Spears K, Paul DR, Harris GK, Rumpler WV et al. A controlled trial of reduced meal frequency without caloric restriction in healthy, normal-weight, middle-aged adults. *Am J Clin Nutr.* (2007) 85:981–8. doi: 10.1093/ajcn/85.4.981
- Teng NI, Shahar S, Rajab NF, Manaf ZA, Johari MH, Ngah WZ. Improvement of metabolic parameters in healthy older adult men following a fasting calorie restriction intervention. *Aging Male.* (2013) 16:177–83. doi: 10.3109/13685538.2013.832191
- Teng NI, Shahar S, Manaf ZA, Das SK, Taha CS, Ngah WZ. Efficacy of fasting calorie restriction on quality of life among aging men. *Physiol Behav.* (2011) 104:1059–64. doi: 10.1016/j.physbeh.2011.07.007
- 50. Tinsley GM, Forsse JS, Butler NK, Paoli A, Bane AA, La Bounty PM et al. Time-restricted feeding in young men performing resistance training: a randomized controlled trial. *Eur J Sport Sci.* (2017) 17:200–7. doi: 10.1080/17461391.2016.1223173
- Tinsley GM, Moore ML, Graybeal AJ, Paoli A, Kim Y, Gonzales JU et al. Timerestricted feeding plus resistance training in active females: a randomized trial. *Am J Clin Nutr.* (2019) 110:628–40. doi: 10.1093/ajcn/nqz126
- Trabelsi K, Stannard SR, Ghlissi Z, Maughan RJ, Kallel C, Jamoussi K et al. Effect of fed- versus fasted state resistance training during Ramadan on body composition and selected metabolic parameters in bodybuilders. J Int Soc Sports Nutr. (2013) 10:23. doi: 10.1186/1550-2783-10-23
- Varady KA, Bhutani S, Klempel MC, Kroeger CM, Trepanowski JF, Haus JM et al. Alternate day fasting for weight loss in normal weight and overweight subjects: a randomized controlled trial. *Nutr J.* (2013) 12:146. doi: 10.1186/1475-2891-12-146
- Zouhal H, Bagheri R, Ashtary-Larky D, Wong A, Triki R, Hackney AC et al. Effects of Ramadan intermittent fasting on inflammatory and biochemical biomarkers in males with obesity. *Physiol Behav.* (2020) 225:113090. doi: 10.1016/j.physbeh.2020.113090
- Rajpal A, Ismail-Beigi F. Intermittent fasting and 'metabolic switch': Effects on metabolic syndrome, prediabetes and type 2 diabetes. *Diabetes Obes Metab.* (2020) 22:1496–510. doi: 10.1111/dom.14080
- 56. Buschemeyer WC. 3rd, Klink JC, Mavropoulos JC, Poulton SH, Demark-Wahnefried W, Hursting SD, et al. Effect of intermittent fasting with or

without caloric restriction on prostate cancer growth and survival in SCID mice. *Prostate.* (2010) 70:1037–43. doi: 10.1002/pros.21136

- Mattson MP, Longo VD, Harvie M. Impact of intermittent fasting on health and disease processes. *Ageing Res Rev.* (2017) 39:46–58. doi: 10.1016/j.arr.2016.10.005
- Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. *Cell Metab.* (2014) 19:181–92. doi: 10.1016/j.cmet.2013.12.008
- Washburn RL, Cox JE, Muhlestein JB, May HT, Carlquist JF, Le VT, et al. Pilot study of novel intermittent fasting effects on metabolomic and trimethylamine n-oxide changes during 24-hour water-only fasting in the FEELGOOD Trial. *Nutrients*. (2019) 11. doi: 10.3390/nu11020246
- Cai H, Qin YL, Shi ZY, Chen JH, Zeng MJ, Zhou W, et al. Effects of alternateday fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. *BMC Gastroenterol.* (2019) 19:219. doi: 10.26402/jpp.2018.5.02
- 61. Trepanowski JF, Kroeger CM, Barnosky A, Klempel MC, Bhutani S, Hoddy KK et al. Effect of alternate-day fasting on weight loss, weight maintenance, and cardioprotection among metabolically healthy obese adults: a randomized clinical trial. *JAMA Intern Med.* (2017) 177:930–8. doi: 10.1001/jamainternmed.2017.0936
- Halpern B, Mendes TB. Intermittent fasting for obesity and related disorders: unveiling myths, facts, and presumptions. *Arch Endocrinol Metab.* (2021) 65:14–23. doi: 10.20945/2359-3997000000322
- Varady KA. Intermittent versus daily calorie restriction: which diet regimen is more effective for weight loss? *Obes Rev.* (2011) 12:e593–601. doi: 10.1111/j.1467-789X.2011.00873.x
- Heilbronn LK, Smith SR, Martin CK, Anton SD, Ravussin E. Alternateday fasting in nonobese subjects: effects on body weight, body composition, and energy metabolism. *Am J Clin Nutr.* (2005) 81:69–73. doi: 10.1093/ajcn/81.1.69
- Hirschberg AL. Sex hormones, appetite and eating behaviour in women. Maturitas. (2012) 71:248–56. doi: 10.1016/j.maturitas.2011.12.016
- 66. Hill JO, Schlundt DG, Sbrocco T, Sharp T, Pope-Cordle J, Stetson B et al. Evaluation of an alternating-calorie diet with and without exercise in the treatment of obesity. Am J Clin Nutr. (1989) 50:248–54. doi: 10.1093/ajcn/50.2.248
- Redman LM, Martin CK, Williamson DA, Ravussin E. Effect of caloric restriction in non-obese humans on physiological, psychological and behavioral outcomes. *Physiol Behav.* (2008) 94:643–8. doi: 10.1016/j.physbeh.2008.04.017
- Most J, Redman LM. Impact of calorie restriction on energy metabolism in humans. *Exp Gerontol.* (2020) 133:110875. doi: 10.1016/j.exger.2020.110875
- de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. N Engl J Med. (2019) 381:2541–51. doi: 10.1056/NEJMra1905136
- Mattson MP, Allison DB, Fontana L, Harvie M, Longo VD, Malaisse WJ, et al. Meal frequency and timing in health and disease. *Proc Natl Acad Sci U S A*. (2014) 111:16647–53. doi: 10.1073/pnas.1413965111
- Omodei D, Fontana L. Calorie restriction and prevention of age-associated chronic disease. *FEBS Lett.* (2011) 585:1537–42. doi: 10.1016/j.febslet.2011.03.015
- 72. Jacob E, Avery A. Energy-restricted interventions are effective for the remission of newly diagnosed type 2 diabetes: A systematic review of the evidence base. Obes Sci Pract. (2021) 7:606–18. doi: 10.1002/osp4.504
- Challet E. The circadian regulation of food intake. Nat Rev Endocrinol. (2019) 15:393–405. doi: 10.1038/s41574-019-0210-x
- 74. Sutton EF, Beyl R, Early KS, Cefalu WT, Ravussin E, Peterson CM. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. *Cell Metab.* (2018) 27:1212–21.e1213. doi: 10.1016/j.cmet.2018.04.010
- 75. Stachowicz A, Zabczyk M, Natorska J, Suski M, Olszanecki R, Korbut R, et al. Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. *Sci Rep.* (2018) 8:17301. doi: 10.1038/s41598-018-35034-x
- Patikorn C, Roubal K, Veettil SK, Chandran V, Pham T, Lee YY, et al. Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials. *JAMA Netw Open.* (2021) 4:e2139558. doi: 10.1001/jamanetworkopen.2021.39558

- 77. Harris L, Hamilton S, Azevedo LB, Olajide J, De Brún C, Waller G, et al. Intermittent fasting interventions for treatment of overweight and obesity in adults: a systematic review and meta-analysis. *JBI Database System Rev Implement Rep.* (2018) 16:507–47. doi: 10.11124/JBISRIR-2016-0 03248
- 78. Yang F, Liu C, Liu X, Pan X, Li X, Tian L, et al. Effect of epidemic intermittent fasting on cardiometabolic risk factors: a systematic review and meta-analysis of randomized controlled trials. *Front Nutr.* (2021) 8:669325. doi: 10.3389/fnut.2021. 669325

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Gu, Fu, Hong, Ni, Yu and Lou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.